AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Article
January 16, 2019
Open Access

Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting

Ganesh Chauhan, PhD, Hieab H.H. Adams, PhD, Claudia L. Satizabal, PhD, Joshua C. Bis, PhD, Alexander Teumer, PhD https://orcid.org/0000-0002-8309-094X, Muralidharan Sargurupremraj, PhD, Edith Hofer, PhD, … Show All … , Stella Trompet, PhD, Saima Hilal, PhD, Albert Vernon Smith, PhD, Xueqiu Jian, PhD, Rainer Malik, PhD, Matthew Traylor, PhD, Sara L. Pulit, PhD https://orcid.org/0000-0002-2502-3669, Philippe Amouyel, MD, Bernard Mazoyer, MD, PhD, Yi-Cheng Zhu, MD, Sara Kaffashian, PhD, Sabrina Schilling, PhD, Gary W. Beecham, PhD, Thomas J. Montine, MD, Gerard D. Schellenberg, PhD, Olafur Kjartansson, MD, Vilmundur Guðnason, MD, PhD, David S. Knopman, MD, Michael E. Griswold, PhD, B. Gwen Windham, MD, Rebecca F. Gottesman, MD, Thomas H. Mosley, PhD, Reinhold Schmidt, MD, Yasaman Saba, MSc, Helena Schmidt, MD, Fumihiko Takeuchi, PhD, Shuhei Yamaguchi, MD, Toru Nabika, MD, Norihiro Kato, MD, Kumar B. Rajan, PhD, Neelum T. Aggarwal, MD, Philip L. De Jager, MD, Denis A. Evans, MD, Bruce M. Psaty, MD, Jerome I. Rotter, MD, Kenneth Rice, PhD, Oscar L. Lopez, MD, Jiemin Liao, MA, Christopher Chen, FRCP, Ching-Yu Cheng, MD, Tien Y. Wong, MD, Mohammad K. Ikram, MD, Sven J. van der Lee, MD, Najaf Amin, PhD, Vincent Chouraki, MD, Anita L. DeStefano, PhD, Hugo J. Aparicio, MD, Jose R. Romero, MD, Pauline Maillard, PhD, Charles DeCarli, MD, Joanna M. Wardlaw, MD, Maria del C. Valdés Hernández, PhD, Michelle Luciano, PhD, David Liewald, BSc, Ian J. Deary, PhD, John M. Starr, PhD, Mark E. Bastin, PhD, Susana Muñoz Maniega, PhD https://orcid.org/0000-0001-5185-6384, P. Eline Slagboom, PhD, Marian Beekman, PhD https://orcid.org/0000-0003-0585-6206, Joris Deelen, PhD, Hae-Won Uh, PhD, Robin Lemmens, MD, Henry Brodaty, MD, Margaret J. Wright, PhD, David Ames, MD, Giorgio B. Boncoraglio, MD, Jemma C. Hopewell, PhD, Ashley H. Beecham, MS, Susan H. Blanton, PhD, Clinton B. Wright, MD, Ralph L. Sacco, MD, Wei Wen, PhD, Anbupalam Thalamuthu, PhD, Nicola J. Armstrong, PhD, Elizabeth Chong, PhD, Peter R. Schofield, PhD https://orcid.org/0000-0003-2967-9662, John B. Kwok, PhD https://orcid.org/0000-0001-9574-6195, Jeroen van der Grond, PhD, David J. Stott, MBChB, MD, Ian Ford, PhD, J. Wouter Jukema, MD, Meike W. Vernooij, MD, Albert Hofman, MD, André G. Uitterlinden, PhD, Aad van der Lugt, MD, Katharina Wittfeld, PhD, Hans J. Grabe, MD https://orcid.org/0000-0003-3684-4208, Norbert Hosten, MD, Bettina von Sarnowski, MD, Uwe Völker, PhD, Christopher Levi, BMedSci, FRACP, Jordi Jimenez-Conde, MD, Pankaj Sharma, MD, PhD, Cathie L.M. Sudlow, FRCP(Ed), Jonathan Rosand, MD, Daniel Woo, MD, John W. Cole, MD, James F. Meschia, MD, Agnieszka Slowik, MD, Vincent Thijs, MD https://orcid.org/0000-0002-6614-8417, Arne Lindgren, MD, Olle Melander, MD, Raji P. Grewal, MD, Tatjana Rundek, MD, Kathy Rexrode, MD, Peter M. Rothwell, MD, Donna K. Arnett, PhD, Christina Jern, MD, Julie A. Johnson, PharmD, Oscar R. Benavente, MD, Sylvia Wasssertheil-Smoller, PhD, Jin-Moo Lee, MD, PhD, Quenna Wong, MS, Braxton D. Mitchell, PhD, Stephen S. Rich, PhD, Patrick F. McArdle, PhD, Mirjam I. Geerlings, PhD, Yolanda van der Graaf, MD, PhD, Paul I.W. de Bakker, PhD https://orcid.org/0000-0001-7735-7858, Folkert W. Asselbergs, MD https://orcid.org/0000-0002-1692-8669, Velandai Srikanth, FRACP, Russell Thomson, PhD, Rebekah McWhirter, PhD, Chris Moran, FRACP, Michele Callisaya, PhD, Thanh Phan, FRACP, Loes C.A. Rutten-Jacobs, PhD https://orcid.org/0000-0003-3223-885X, Steve Bevan, PhD, Christophe Tzourio, MD, PhD https://orcid.org/0000-0002-6517-2984, Karen A. Mather, PhD, Perminder S. Sachdev, MD, Cornelia M. van Duijn, PhD, Bradford B. Worrall, MD, Martin Dichgans, MD, Steven J. Kittner, MD, Hugh S. Markus, FMedSci, Mohammad A. Ikram, MD, Myriam Fornage, PhD, Lenore J. Launer, PhD, Sudha Seshadri, MD, W.T. Longstreth Jr, MD, and Stéphanie Debette, MD on behalf of the Stroke Genetics Network (SiGN), the International Stroke Genetics Consortium (ISGC), METASTROKE, Alzheimer's Disease Genetics Consortium (ADGC), and the Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) ConsortiumAuthors Info & Affiliations
January 29, 2019 issue
92 (5) e486-e503
https://doi.org/10.1212/WNL.0000000000006851
Letters to the Editor
Track CitationsAdd to favorites
Short Formfull text

Abstract

Objective

To explore genetic and lifestyle risk factors of MRI-defined brain infarcts (BI) in large population-based cohorts.

Methods

We performed meta-analyses of genome-wide association studies (GWAS) and examined associations of vascular risk factors and their genetic risk scores (GRS) with MRI-defined BI and a subset of BI, namely, small subcortical BI (SSBI), in 18 population-based cohorts (n = 20,949) from 5 ethnicities (3,726 with BI, 2,021 with SSBI). Top loci were followed up in 7 population-based cohorts (n = 6,862; 1,483 with BI, 630 with SBBI), and we tested associations with related phenotypes including ischemic stroke and pathologically defined BI.

Results

The mean prevalence was 17.7% for BI and 10.5% for SSBI, steeply rising after age 65. Two loci showed genome-wide significant association with BI: FBN2, p = 1.77 × 10−8; and LINC00539/ZDHHC20, p = 5.82 × 10−9. Both have been associated with blood pressure (BP)–related phenotypes, but did not replicate in the smaller follow-up sample or show associations with related phenotypes. Age- and sex-adjusted associations with BI and SSBI were observed for BP traits (p value for BI, p[BI] = 9.38 × 10−25; p[SSBI] = 5.23 × 10−14 for hypertension), smoking (p[BI] = 4.4 × 10−10; p[SSBI] = 1.2 × 10−4), diabetes (p[BI] = 1.7 × 10−8; p[SSBI] = 2.8 × 10−3), previous cardiovascular disease (p[BI] = 1.0 × 10−18; p[SSBI] = 2.3 × 10−7), stroke (p[BI] = 3.9 × 10−69; p[SSBI] = 3.2 × 10−24), and MRI-defined white matter hyperintensity burden (p[BI] = 1.43 × 10−157; p[SSBI] = 3.16 × 10−106), but not with body mass index or cholesterol. GRS of BP traits were associated with BI and SSBI (p ≤ 0.0022), without indication of directional pleiotropy.

Conclusion

In this multiethnic GWAS meta-analysis, including over 20,000 population-based participants, we identified genetic risk loci for BI requiring validation once additional large datasets become available. High BP, including genetically determined, was the most significant modifiable, causal risk factor for BI.

Introduction

Brain infarcts (BI) detected on MRI are commonly seen in older persons, being described in 8%–28% of participants in population-based cohort studies.1 Most MRI-defined BI are covert, not being associated with overt, clinical stroke symptoms.2,3 Nonetheless, they cannot be considered silent or benign, as they are often associated with subtle neurologic symptoms and with increased risk of future stroke, cognitive decline, and in some studies dementia.4,5 Most MRI-defined BI are small subcortical BI (SSBI), believed to be primarily caused by small vessel disease (SVD).6
Mechanisms and predictors of BI and SSBI remain incompletely understood. No genetic risk variants for BI and SSBI have been consistently identified to date,7–16 and findings with vascular risk factors have been inconsistent.1 Partly reflecting this uncertainty, recommendations to direct clinicians on how to best manage covert MRI-defined BI are lacking.
To enhance understanding of risk factors for BI and SSBI, we first conducted a large meta-analysis of genome-wide association studies (GWAS) from 18 population-based studies, comprising 20,949 participants from 5 ethnic groups, using the 1000 Genomes reference panel (1000G), more than doubling the size of a prior GWAS.16 Second, we examined the association of vascular risk factors with BI and SSBI in this large sample, using both vascular risk factor measurements and their genetic risk scores (GRS).

Methods

Study design and samples

The meta-analyses included 18 prospective population-based cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (table e-1 and additional Methods e-1, https://doi.org/10.5061/dryad.hk07677). Although the cohorts contributing participants are longitudinal, this study is cross-sectional, based on the analysis of BI and SSBI at one timepoint in the subset of cohort participants with brain MRI. These cohorts comprised 5 ethnic groups and ancestries: European (n = 17,956), African (n = 1,834), Hispanic (n = 737), Malay (n = 215), and Chinese (n = 207). Some cohorts contributed to data for more than one ethnic group, resulting in a total of 23 datasets (tables e-1 to e-3, https://doi.org/10.5061/dryad.hk07677). Out of a total of 20,949 participants, 3,726 had MRI-defined BI. We did not exclude participants with a history of overt, clinically defined stroke prior to the MRI, except in 4 cohorts where patients with history of stroke were excluded by design. Three datasets did not contribute to the SSBI analysis either due to small numbers or absence of BI subtyping. Out of a total of 19,073 participants in the remaining 20 datasets, 3,533 had BI, of whom 2,021 (57.2%) had SSBI.

Variable definitions

Detailed MRI scanning protocols, as well as BI and SSBI definitions, for each study are described in table e-4 (https://doi.org/10.5061/dryad.hk07677). All protocols comprised at least T1, T2, and proton density or fluid-attenuated inversion recovery (FLAIR) sequences. On MRI, BI were defined as an area of abnormal signal intensity lacking mass effect with a size ≥3–4 mm; in the white matter, they were required to be hypointense on T1-weighted images, approaching the hypointensity of CSF, to distinguish them from diffuse white matter lesions; and they were distinguished from dilated perivascular spaces based on their irregular shape, presence of a hyperintense rim in FLAIR, and absence of a typical vascular shape following the orientation of perforating vessels.17 SSBI corresponded to BI with a size <15–20 mm, located in the basal ganglia, the white matter, or the brainstem. Participants with large BI or BI located in the cerebral cortex or cerebellum were excluded from analyses of SSBI. We also measured burden of white matter hyperintensities (WMH), a quantitative MRI marker of SVD, corresponding to signal abnormalities of variable size in the white matter, appearing as hyperintensity on T2-weighted or FLAIR images, but without cavitation. Details of WMH measurements have been described previously.18

Vascular risk factors

Vascular risk factor levels measured closest to brain MRI acquisition were used. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg or use of one or more blood pressure (BP)–lowering medications. We defined pulse pressure (PP) as the difference between SBP and DBP and mean arterial pressure (MAP) as DBP + 1/3 × PP. Diabetes was defined as a previous diagnosis of diabetes, a fasting plasma glucose >7.0 mmol/L, or antidiabetic drug use. Fasting serum total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured using enzymatic methods. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. Body mass index (BMI) was defined as the ratio of weight (kg) to the square of height (m). Active smoking was defined according to study-specific criteria. History of overt, clinically defined stroke and other cardiovascular events was based on ongoing surveillance prior to brain MRI acquisition in most studies since participant recruitment had started prior to the initial brain MRI. In studies that had brain MRI scanning at the initial visit, the history and examination at this visit were used to identify prior overt, clinically defined stroke. History of cardiovascular events included history of angina, myocardial infarction, cardiac bypass surgery, angioplasty, or peripheral vascular disease.

Genotypes

All participating discovery cohorts had genome-wide genotypes imputed on the 1000G (phase 1, version 3).19 Genome-wide genotyping platforms, quality control measures, and imputation parameters used in each study are presented in tables e-5–e-7 (https://doi.org/10.5061/dryad.hk07677).

Genome-wide association analyses with BI and small subcortical BI

For genome-wide association analyses with BI and SSBI, each study performed logistic regression under an additive genetic model after adjusting for age, sex, principal components of population stratification, and additional study-specific covariates, such as study site or family structure, as needed (additional Methods e-2, https://doi.org/10.5061/dryad.hk07677, for centralized quality control description). Our primary multiethnic GWAS meta-analysis was performed using MANTRA, based on a Bayesian framework.20 In secondary analyses, we also ran the multiethnic GWAS meta-analysis with 2 alternative methods (additional Methods e-2, https://doi.org/10.5061/dryad.hk07677): (1) using fixed effects inverse variance weighting with METAL21,22 and (2) using the random effects meta-analysis model implemented in METASOFT.23 During meta-analysis, genomic control correction was applied to the individual studies and ethnic-specific results to remove any residual inflation of association statistics. We did not observe any systematic inflation of association statistics (figure e-1, https://doi.org/10.5061/dryad.hk07677). Statistical measures from MANTRA, the primary meta-analysis method, were used to define genome-wide significance (Log10 of Bayesian factor [L10BF] > 6)24 and to choose single nucleotide polymorphisms (SNPs) for follow-up (L10BF > 4.5) in either the BI or SSBI meta-analysis. Details of functional annotation of top loci are provided in additional Methods e-3 (https://doi.org/10.5061/dryad.hk07677).

Follow-up and extension

For follow-up and extension studies, genotypes imputed to the 1000G reference panel were available in most instances for in silico look-up of the selected risk variants. Three follow-up studies performed de novo genotyping of the top 6 loci (additional Methods e-1, https://doi.org/10.5061/dryad.hk07677). The lead variant (with lowest p value) was genotyped at each suggestive or genome-wide significant locus, and if not feasible, another variant in strong linkage disequilibrium (LD, r2 > 0.8) was genotyped. A p value <0.0083, correcting for 6 loci, was considered significant evidence for replication.
The follow-up sample, in which we sought to confirm associations observed in the discovery analysis, included 6,862 participants, of whom 1,483 had BI and 630 had SSBI, from 6 community-based studies of European origin and one of Japanese origin (table e-1, https://doi.org/10.5061/dryad.hk07677).
As an extension, to test whether genetic variants associated with MRI-defined BI or SSBI in the discovery analysis are also associated with correlated phenotypes, we first explored their association with ischemic stroke (IS) overall and the small vessel disease subtype (IS-SVD) when available in 4 collaborative studies (table e-1, https://doi.org/10.5061/dryad.hk07677). Second, we explored whether genetic variants associated with MRI-defined BI and SSBI were associated with neuropathologically defined BI based on 2,940 brain autopsies in participants without dementia from the Alzheimer's Disease Genetics Consortium (ADGC). Participants with large infarcts or lacunes (n = 857, 29%) were compared to participants without any infarcts or having only microscopic infarcts (n = 2,083).25
We calculated power of the follow-up and extension studies using Quanto V1.2.3 (biostats.usc.edu/software; table e-8 and figure e-2, https://doi.org/10.5061/dryad.hk07677).

Association of vascular risk factors with BI and SSBI

Individual studies performed logistic regression to test for association of vascular risk factor measurements with presence or absence of at least one BI or SSBI. Analyses were performed with and without adjustments for age and sex. Analyses with BP or lipid traits as the main independent variable were additionally adjusted for treatment with disease-specific medications, and association analyses with fasting plasma glucose were limited to participants without type 2 diabetes. Except for WMH burden, the regression coefficients and standard errors for risk factors in the individual studies belonging to one ethnic group were combined using fixed-effects inverse variance-weighted meta-analysis and subsequently the betas and standard errors obtained in each ethnic group were combined using fixed-effects inverse variance-weighted meta-analysis, in the absence of heterogeneity (p < 1 × 10−6), to derive the multiethnic meta-analysis estimates. For WMH burden, the statistics were combined using the Z score–based sample size weighted meta-analysis as WMH burden was measured on different scales in participating studies.18
We then explored whether genetic variants previously shown in published GWAS to be associated with specific vascular risk factors were, in aggregate, also associated with BI and SSBI. This approach was selected to assess to what extent genetically determined vascular risk factor levels are associated with BI and SSBI and to provide evidence for a causal relation between a given vascular risk factor and risk of BI or SSBI, provided that Mendelian randomization assumptions are fulfilled.26 We combined known genetic risk variants for each individual vascular risk factor into a weighted GRS, using effect estimates from the largest published GWAS of that risk factor as weights. We then tested for association of these GRS with BI and SSBI using the inverse-variance weighting (IVW) method. Construction of the GRS, selection of variants for the GRS analysis, as well as effect estimates used as weights are detailed in additional Methods e-4 and tables e-9–e-12 (https://doi.org/10.5061/dryad.hk07677). For significant GRS associations with BI or SSBI, we further conducted sensitivity analyses using the MR-Egger method implemented as an R package (TwoSampleMR),27 which unlike the IVW method estimates the intercept term as part of the analysis. An intercept term significantly differing from zero suggests the presence of directional (unbalanced) pleiotropy, meaning that the pleiotropic effects of genetic variants are not balanced about the null.27 We used a conservative significance threshold of p < 0.05 for the intercept.
After Bonferroni correction for 12 independent vascular phenotypes tested for association with BI and SSBI, p < 0.0042 was considered significant for associations with vascular risk factor measurements or GRS. The number of independent vascular phenotypes, taking into account correlation between the phenotypes considered, was estimated based on individual level data from the 3C-Dijon study using the online tool matSpDlite (neurogenetics.qimrberghofer.edu.au/matSpDlite/).

Standard protocol approvals, registrations, and patient consents

Institutional review boards approved all of these studies, and all participants provided informed consent.

Data availability

Summary statistics of the top SNPs are available from Dryad for both BI and SSBI. Other data that support the findings of this study are available from the corresponding authors upon reasonable request.

Results

In this large population-based dataset comprising 18 cohort studies, the frequency of MRI-defined BI ranged from 4% to 38% in participating cohorts (table e-1, https://doi.org/10.5061/dryad.hk07677). A description of demographic characteristics in all participants with BI (n = 3,726), with SSBI (n = 2,021), and without BI (n = 17,223) is provided in tables e-2 and e-3 (https://doi.org/10.5061/dryad.hk07677) for individual studies. Participants with BI and SSBI were on average 6 years older and more often men compared to those without BI. In age-stratified analyses, the prevalence of BI and SSBI increased with age, most prominently beyond age 65, after which a 25.8% (range 13.9%–37.0%) increment in BI prevalence was observed compared to participants younger than 65 years (figure 1). Overall, the prevalence of BI ranged from less than 5% before age 50 to over 30% beyond age 80, with similar findings when we analyzed men and women separately (figures e-3 and e-4, https://doi.org/10.5061/dryad.hk07677). Only 11% of those with BI and 9% of those with SSBI had a history of stroke (12.5% and 9.8% when removing cohorts that excluded participants with history of stroke by design); hence, the vast majority of MRI-defined BI were covert.
Figure 1 Prevalence of MRI-defined brain infarcts (BI) and small subcortical brain infarcts (SSBI) by different age groups
CI = confidence interval.
Genome-wide association plots for GWAS of BI and SSBI are displayed in figures e-5 and e-6 (https://doi.org/10.5061/dryad.hk07677). Two loci were associated with risk of BI at genome-wide significant level (L10BF > 6): rs39938 in FBN2 (chr5q23) and rs12583648 in LINC00539 and near ZDHHC20 (chr13q12). In addition, 2 SNPs were associated with BI at a suggestive level of significance (L10BF > 4.5): rs12373108 near CALB2/ZNF23 (chr16q22) and rs74587705 in SV2B (chr15q26) (table 1). No genome-wide significant association was observed for SSBI, but 2 loci reached the threshold for suggestive association (L10BF > 4.5): rs9371194 in PLEKHG1 (chr6q25) and rs75889566 in FRMD1 (chr6q27, table 1). These 6 loci were taken forward for the follow-up stage (table 2). For all SNPs reaching Log10BF > 4.5 in the discovery stage, association statistics are shown in table e-13 and figure e-7 (https://doi.org/10.5061/dryad.hk07677).
Table 1 Loci reaching Log10 of Bayesian factor (L10BF) >4.5 in the discovery stage of the genome-wide association studies with brain infarcts (BI) or small subcortical brain infarcts (SSBI)
Table 2 Follow-up and clinical extension of loci reaching Log10 of Bayesian factor (L10BF) >4.5 in the discovery stage of the genome-wide association studies
In the substantially smaller population-based follow-up studies, we could not replicate the 2 genome-wide significant or the 4 suggestive loci associated with BI or SSBI (table 2). Of the 6 loci that we followed up, we had limited power for 2 of the loci for BI (52%) and 4 of the loci for SSBI (50%–58%) (table e-8, https://doi.org/10.5061/dryad.hk07677). Power estimates in the follow-up study are even lower when accounting for the winner's curse phenomenon, which leads to inflated effect estimates in the discovery cohort.28 One suggestive locus for SSBI (PLEKHG1) showed nominal association with BI and SSBI in the follow-up studies (pBI = 0.03 and pSSBI = 0.02), but in the opposite direction (table 2).
Likewise, none of the genome-wide significant or suggestive loci for BI and SSBI showed association with IS (overall or IS-SVD) or pathologically defined BI in the extension studies after correcting for multiple testing (table 2 and table e-14, https://doi.org/10.5061/dryad.hk07677). Whereas the sample size for overall IS and IS-SVD was relatively large, it was limited for pathologically defined BI, and power was insufficient for 4 of the loci (25%–70%) (table e-8, https://doi.org/10.5061/dryad.hk07677).
Associations of vascular risk factors with risk of BI or SSBI adjusted for age and sex are presented in table 3 (for unadjusted results, see table e-15, https://doi.org/10.5061/dryad.hk07677). Both BI and SSBI were significantly associated with all BP indices, the lowest p value being observed for SBP and MAP. Smoking and diabetes were also associated with both BI and SSBI. Triglycerides were significantly associated with BI only. We did not observe significant associations with levels of HDL cholesterol, LDL cholesterol, BMI, or fasting plasma glucose in nondiabetic participants. Both BI and SSBI were associated with history of cardiovascular disease and history of stroke. The most significant association by far was observed with WMH burden on brain MRI, both for BI and SSBI. As hypertension is an important risk factor for WMH as well, we additionally adjusted the regression model for hypertension to rule out a confounding effect by this variable; however, the association became even more significant (p = 5.71 × 10−172 for BI and p = 4.47 × 10−114 for SSBI) (table e-16, https://doi.org/10.5061/dryad.hk07677). No significant heterogeneity was seen for these associations across participating studies.
Table 3 Association of vascular risk factors with MRI-defined brain infarcts and small subcortical brain infarcts
When exploring the relation of weighted genetic risk scores for vascular risk factors with BI and SSBI, we found that GRS for SBP and MAP were significantly associated with increased risk of BI and SSBI after correction for multiple testing (table 4). In sensitivity analyses using MR-Egger regression, evidence for directional pleiotropy was lacking for these associations between SBP or MAP GRS and BI or SSBI (p intercept >0.36). GRS for DBP, BMI, coronary artery disease, WMH burden, and IS were nominally associated with BI (p < 0.05, table 4), but these associations did not survive correction for multiple testing.
Table 4 Association of genetic risk scores (GRS) for vascular risk factors with brain infarcts and small subcortical brain infarcts

Discussion

This multiethnic meta-analysis comprising over 20,000 community participants provides noteworthy insight into risk factors for MRI-defined brain infarcts. The described BI distributions across different age groups and by sex may also serve as a reference for comparison with BI and SSBI frequency in other settings. Of note, about 90% of BI were covert, not being associated with a history of stroke. In this multiethnic GWAS of BI and SSBI, we identified 2 genome-wide significant risk loci for BI, FBN2 on chr5q23 and LINC00539/ZDHHC20 on chr13q12, although these could not be replicated in a smaller follow-up sample. We further describe the association of MRI-defined BI with vascular risk factors, combining the vast majority of population-based cohort studies with BI and SSBI measurements available. We find high BP, both phenotypically expressed high BP and genetically determined risk for high BP, to be the most significant modifiable risk factor for BI. No association with cholesterol levels or BMI was found.
To identify novel genetic risk loci for MRI-defined BI and SSBI, we have more than doubled the sample size compared to the previously published GWAS of MRI-defined BI,16 used imputed genotypes based on the 1000G reference panel to increase the marker coverage, and included samples from 5 ethnicities for a broader representation of individuals from different origins. Moreover, we studied both BI and SSBI, while only BI were analyzed in the previously published GWAS meta-analysis.16 Our inability to replicate the genome-wide significant and suggestive findings could reflect false-positive results but may also be explained by insufficient power in the follow-up stage (table e-8, https://doi.org/10.5061/dryad.hk07677). Further studies on larger samples with MRI-defined BI are required to confirm or refute these findings. Moreover, while we could not provide evidence for an association of genome-wide significant and suggestive risk loci for BI and SSBI with IS, IS-SVD, or pathologically defined BI, this inability could reflect differences in the biology underlying these phenotypes, as well as limited power in the extension studies.
The 2 loci that crossed the genome-wide significance threshold, while requiring confirmation in larger independent samples, do harbor plausible biological candidates. Fibrillin2 (FBN2) encodes a protein that is part of the connective tissue microfibrils and elastic fiber assembly of the cell.29 Rare and common variants in FBN2 have been associated with age-related macular degeneration.30 Recent studies have also implicated common variants in FBN2 to be associated with SBP,31 although the variants differ (rs6595838-SBP and rs39938-BI, r2 = 0.017). The LINC00539/ZDHHC20 locus was a suggestive hit in a GWAS of adverse metabolic response to hydrochlorothiazide, a drug commonly used to treat hypertension.32 The lead SNP in the region could also influence the expression of the long noncoding RNA LINC00539 (table e-17, https://doi.org/10.5061/dryad.hk07677).
Our findings provide definitive evidence for a major and predominant association of increasing BP levels with increased risk of BI and SSBI.1,33 Beside significant associations with hypertension, a continuous association was observed for increasing levels of all BP measurements (SBP, DBP, PP, MAP), consistent with elevated BP being the major modifiable risk factor for BI, as is the case for overt, clinically defined IS.34–36 The importance and causal nature of the relation between high BP and risk of BI and SSBI is further supported by the significant association of BP genetic risk scores, for SBP and MAP, with increased risk of BI, especially SSBI, with no indication of directional pleiotropy using the MR-Egger approach.27
Previous publications on the association of BI and SSBI with vascular risk factors other than elevated BP were inconsistent.1,33,37 Our study provides evidence for a significant association of current smoking and diabetes with risk of BI and SSBI, while no association with BMI and cholesterol could be demonstrated, despite the very large sample size. These findings are consistent with epidemiologic data on IS.35 Interestingly, in contrast with cholesterol levels, a significant association of increasing triglyceride levels with BI risk was observed, although for SSBI the association did not withstand correction for multiple testing. Inconsistent results have been reported regarding association of triglycerides with overt, clinically defined IS,38,39 but the present results are in line with evidence of an association in older community-dwelling persons between high triglyceride levels and WMH burden, another MRI marker of SVD.40
As previously described, we show a significant association of WMH burden with BI and SSBI, reaching p < 10−100 in this study. Surprisingly, shared genetic variation among the top loci for WMH burden and BI was limited. While this observation could be due to lack of power, it could also suggest that WMH and BI share more environmental than genetic risk factors. A more comprehensive search for shared genetic variation between WMH burden and BI or SSBI at the genome-wide level using the LD score regression method41 could not be performed in the present study due to low variance in the BI GWAS, also hampering the calculation of BI heritability using the same method. Of note, based on estimates from previously published family-based studies, heritability for SSBI was described to be low at 29%, in contrast with a moderate to high heritability for WMH burden at 49%–80%.42–44 Hypertension is a major risk factor for WMH as well, and a BP GRS was also significantly associated with WMH burden in a prior study.18 However, the association of WMH burden with BI and SSBI was still significant after adjusting for hypertension status (table 3), or for SBP levels and BP-lowering treatment (table e-16, https://doi.org/10.5061/dryad.hk07677), suggesting that BP is not the only mediator of this association.
An important strength of the present study is that we have gathered nearly all large population-based studies with MRI-based identification of BI, genome-wide genotypes, and detailed vascular risk factor and comorbidity assessment, totaling over 20,000 participants covering 5 ethnic groups. Despite the unprecedented sample size, we were underpowered for the discovery of novel, robust genetic risk loci and even more so for the follow-up of genome-wide significant findings. Our ability to discover robust genetic risk variants may also have been hampered by the heterogeneity in BI and SSBI etiology, even though SVD is likely the predominant mechanism,45 and by some heterogeneity in the way BI and SSBI have been measured in participating studies. Finally, although the majority of participants had covert BI, 10% had a history of overt, clinically defined stroke, but including both covert and overt BI also enables a better representation of the spectrum of participants with MRI-defined BI in the general population. Whereas history of stroke was more common in participants with BI than those without, we do not believe that this inclusion has driven the associations we observed, given both the small number of participants with a stroke history and the significance level of the observed associations. Moreover, in this population-based setting, determining whether an MRI-defined BI could be attributed to the history of clinically defined stroke was not always possible.
In clinical practice, MRI-defined BI are commonly seen on brain MRI scans performed for various reasons in older persons. They have been shown to be powerful predictors of incident stroke and incident dementia.1,4,46 Hence BI represent an important marker for detection of high-risk individuals and initiation of preventive interventions. However, no randomized trials and no recommendations are currently available for the management of covert MRI-defined BI. The observational evidence is overwhelming for a strong causal relation between high BP and risk of BI and SSBI. A randomized trial will be needed to decide if persons with MRI-defined BI will benefit from more intensive BP-lowering strategies than is recommended currently for primary prevention.
This multiethnic, population-based study on 20,949 participants sheds important new light on susceptibility factors of MRI-defined brain infarcts, a marker of covert vascular brain injury commonly observed in older persons.

Author affiliations

From the Bordeaux Population Health Research Center (G.C., M.S., S.K., S. Schilling, C.T., S.D.), INSERM U1219, Groupe d'Imagerie Neurofonctionnelle CNRS/CEAU5293 (B.M.), and University of Bordeaux (G.C., C.T., M.S., S.K., S. Schilling, S.D., B.M.), Department of Neurology, Bordeaux University Hospital (S.D.), Bordeaux, France; Departments of Epidemiology (H.H.H.A., M.W.V., A.H., M.A.I.), Radiology & Nuclear Medicine (H.H.H.A., M.W.V., A.v.d.L., M.A.I.), Internal Medicine (A.G.U.), and Neurology (M.A.I.), Erasmus MC, Rotterdam, the Netherlands; Department of Neurology (C.L.S., V.C., H.J.A., J.R.R., P.M., S. Seshadri), Boston University School of Medicine; Department of Biostatistics (A.L.D., S. Seshadri), Boston University School of Public Health; The National Heart, Lung, and Blood Institute's Framingham Heart Study (C.L.S., V.C., A.L.D., H.J.A., J.R.R., P.M., S. Seshadri), MA; Cardiovascular Health Research Unit, Department of Medicine (J.C.B., B.M.P.), and Departments of Epidemiology (B.M.P., W.T.L.), Health Services (B.M.P.), Biostatistics (K. Rice, Q.W.), Neurology (W.T.L.), and Pathology (T.J.M.), University of Washington, Seattle; Pathology (T.J.M.), Standford University, California; Institute for Community Medicine (A. Teumer), Department of Psychiatry and Psychotherapy (H.J.G.), Institute of Diagnostic Radiology and Neuroradiology (N.H.), and Department of Neurology (B.v.S.), University Medicine Greifswald, Germany; Clinical Division of Neurogeriatrics, Department of Neurology (E.H., R.S.), Institute for Medical Informatics, Statistics and Documentation (E.H.), and Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging), Institute of Molecular Biology and Biochemistry (Y.S., H.S.), Medical University of Graz, Austria; Department of Cardiology (S.T., J.W.J.), Section of Gerontology and Geriatrics, Department of Internal Medicine (S.T.), Molecular Epidemiology (P.E.S., M.B., J.D.), Medical Statistics and Bioinformatics (H.-W.U.), and Department of Radiology (J.v.d.G.), Leiden University Medical Center, the Netherlands; Department of Pharmacology (S.H., C.C., M.K.I.) and Department of Ophthalmology, Yong Loo Lin School of Medicine (C.-Y.C.), National University of Singapore; Icelandic Heart Association (A.V.S., V.G.), Kópavogur, Iceland; Institute of Molecular Medicine (X.J., M.F.) and Human Genetics Center (M.F.), University of Texas Health Science Center at Houston; Institute for Stroke and Dementia Research (R.M., M.D.), Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany; Clinical Neurosciences (M.T., L.C.A.R.-J., H.S.M.), University of Cambridge, UK; School of Life Sciences (S.B.), University of Lincoln, United Kingdom; German Center for Neurodegenerative Diseases (DZNE) (L.C.A.R.-J.), Population Health Sciences, Bonn, Germany; Department of Medical Genetics (S.L.P.), Department of Neurology, Brain Center Rudolf Magnus (M.K.I.), Department of Epidemiology, Julius Center for Health Sciences and Primary Care (M.I.G., Y.v.d.G.), Department of Genetics, Center for Molecular Medicine (P.I.W.d.B.), and Department of Cardiology, Division Heart & Lungs (F.W.A.), University Medical Center Utrecht, and Utrecht University, the Netherlands; Institut Pasteur de Lille (V.C., P.A.), Lille University, INSERM, Lille University Hospital, France; Department of Neurology (Y.-C.Z.), Peking Union Medical College Hospital, Beijing, China; John P. Hussman Institute for Human Genomics (G.W.B., A.H.B., S.H.B.), Department of Neurology (R.L.S., T.R.), Evelyn F. McKnight Brain Institute (R.L.S., T.R.), Department of Epidemiology and Public Health Sciences (R.L.S., T.R.), and Dr. John T. Macdonald Foundation Department of Human Genetics (R.L.S., S.H.B., A.H.B.), Miller School of Medicine, University of Miami, FL; Department of Pathology and Laboratory Medicine (G.D.S.), University of Pennsylvania School of Medicine, Philadelphia; Departments of Neurology & Radiology (O.K.), Landspitali National University Hospital; Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Departments of Data Science (M.E.G.) and Medicine (B.G.W., T.H.M.), University of Mississippi Medical Center, Jackson; Department of Neurology (R.F.G.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Gene Diagnostics and Therapeutics (F.T., N.K.), Research Institute, National Center for Global Health and Medicine, Tokyo; The Third Department of Internal Medicine (S.Y.) and Department of Functional Pathology (T.N.), Shimane University School of Medicine, Japan; Rush University Medical Center (K.B.R., N.T.A., D.A.E.), Chicago, IL; Brigham and Women's Hospital (K. Rexrode); Center for Translational & Computational Neuroimmunology, Department of Neurology (P.L.D.J.), Columbia University Medical Center, New York, NY; Kaiser Permanente Washington Health Research Institute (B.M.P.), Seattle, WA; Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, and Division of Genomic Outcomes, Department of Pediatrics (J.I.R.), Harbor-UCLA Medical Center, Torrance; Departments of Pediatrics, Medicine, and Human Genetics (J.I.R.), UCLA, Los Angeles, CA; Department of Neurology (O.L.L.), University of Pittsburgh, PA; Singapore Eye Research Institute (J.L.); Duke-NUS Graduate Medical School (C.-.YC., T.Y.W., M.K.I.), Singapore; Singapore Eye Research Institute (C.-.YC., T.Y.W., M.K.I.), Singapore National Eye Centre; Memory Aging & Cognition Centre (MACC), National University Health System (M.K.I.), Singapore; Genetic Epidemiology Unit, Department of Epidemiology and Biostatistics (S.J.v.d.L., N.A., C.M.v.D.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Neurology (C.D.), University of California at Davis; Brain Research Imaging Centre (J.M.W., M.d.C.V.H., M.E.B., S.M.M.), Centre for Clinical Brain Sciences (J.M.W., M.d.C.V.H., M.E.B., C.L.M.S.), Edinburgh Dementia Research Centre (J.M.W., M.d.C.V.H.), Centre for Cognitive Ageing and Cognitive Epidemiology (J.M.W., M.d.C.V.H., M.L., D.L., I.J.D., M.E.B., J.M.S., S.M.M.), Alzheimer Scotland Dementia Research Centre (J.M.S.), and Institute of Genetics and Molecular Medicine (C.L.M.S.), University of Edinburgh, UK; Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND) (R.L.), KU Leuven–University of Leuven; Center for Brain & Disease Research (R.L.), VIB, Laboratory of Neurobiology; Department of Neurology (R.L.), University Hospitals Leuven, Belgium; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Australia; Centre for Healthy Brain Ageing, Psychiatry (H.B., W.W., A. Thalamuthu, N.J.A., E.C., K.A.M., P.S.S.), Dementia Centre for Research Collaboration (H.B.), and School of Medical Sciences (P.R.S., J.B.K.), University of New South Wales, Sydney; Mathematics & Statistics (N.J.A.), Murdoch University, Perth; Neuroscience Research Australia (K.A.M., P.R.S., A.Thalamuthu), Randwick; Brain and Mind Centre (J.B.K.), The University of Sydney, Camperdown; Queensland Brain Institute (M.J.W.), University of Queensland, Brisbane; National Ageing Research Institute (D.A.), Melbourne; Academic Unit for Psychiatry of Old Age (D.A.), University of Melbourne, Australia; Department of Cerebrovascular Diseases (G.B.B.), Fondazione IRCCS Istituto Neurologico “Carlo Besta,” Milan, Italy; CTSU, Nuffield Department of Population Health (J.C.H., C.M.v.D.), and Nuffield Department of Clinical Neurosciences (P.M.R.), University of Oxford, UK; National Institute of Neurological Disorders and Stroke (C.B.W.), NIH, Bethesda, MD; Institute of Cardiovascular and Medical Sciences, Faculty of Medicine (D.J.S.), and Robertson Centre for Biostatistics (I.F.), University of Glasgow, UK; German Center for Neurodegenerative Diseases (DZNE) (K.W., H.J.G.), Site Rostock, Greifswald, Germany; Interfaculty Institute for Genetics and Functional Genomics (U.V.), University of Greifswald, Germany; John Hunter Hospital (C.L.), Hunter Medical Research Institute and University of Newcastle, Callaghan, Australia; Neurovascular Research Group (NEUVAS) (J.J.-C.), Neurology Department, IMIM–Hospital del Mar, Barcelona, Spain; Institute of Cardiovascular Research (P.S.), Royal Holloway University of London & St Peters and Ashford Hospital, UK; Center for Human Genetic Research and Department of Neurology (J.R.), Program in Medical and Population Genetics, Broad Institute, Massachusetts General Hospital, Harvard Medical School, Boston; University of Cincinnati College of Medicine (D.W.), OH; Department of Neurology (J.W.C., S.J.K.), University of Maryland School of Medicine and Baltimore VAMC; Department of Neurology (J.F.M.), Mayo Clinic Jacksonville, FL; Department of Neurology (A.S.), Jagiellonian University, Krakow, Poland; Department of Clinical Sciences Lund, Neurology (A.L.), Lund University; Department of Neurology and Rehabilitation Medicine (A.L.), Skåne University Hospital; Department of Clinical Sciences Malmö (O.M.), Lund University, Sweden; Neuroscience Institute (R.P.G.), Saint Francis Medical Center, School of Health and Medical Sciences, Seton Hall University, South Orange, NJ; College of Public Health (D.K.A.), University of Kentucky, Lexington; Institute of Biomedicine (C.J.), the Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy (J.A.J.), and Division of Cardiovascular Medicine, College of Medicine (J.A.J.), University of Florida, Gainesville; Department of Neurology (O.R.B.), University of British Columbia, Vancouver, Canada; Department of Epidemiology and Population Health (S.W.-S.), Albert Einstein College of Medicine, Bronx, NY; Stroke Center, Department of Neurology (J.-M.L.), Washington University School of Medicine, St. Louis, MO; Department of Medicine (B.D.M., P.F.M.), University of Maryland School of Medicine, Baltimore; Center for Public Health Genomics (S.S.R.), University of Virginia School of Medicine, Charlottesville; Durrer Center for Cardiovascular Research (F.W.A.), Netherlands Heart Institute, Utrecht, the Netherlands; Institute of Cardiovascular Science, Faculty of Population Health Sciences (F.W.A.), and Farr Institute of Health Informatics Research and Institute of Health Informatics (F.W.A.), University College London, UK; Peninsula Clinical School (V.S., C.M., M.C.), Frankston Hospital, Central Clinical School, and School of Clinical Sciences (T.P.), Monash Health, Monash University, Melbourne; Menzies Institute for Medical Research (V.S., R.M., M.C.), University of Tasmania, Hobart; Western Sydney University (R.T.), New South Wales, Australia; Departments of Neurology and Public Health Sciences (B.B.W.), University of Virginia, Charlottesville; Neuropsychiatric Institute (P.S.S.), Prince of Wales Hospital, Randwick, Australia; Munich Cluster for Systems Neurology (SyNergy) (M.D.), Munich, Germany; Intramural Research Program (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Sciences Center and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (C.L.S., S. Seshadri), San Antonio.

Glossary

1000G
1000 Genomes reference panel
BI
brain infarcts
BMI
body mass index
BP
blood pressure
DBP
diastolic blood pressure
FLAIR
fluid-attenuated inversion recovery
GRS
genetic risk scores
GWAS
genome-wide association studies
HDL
high-density lipoprotein
IS
ischemic stroke
IS-SVD
small vessel disease subtype of ischemic stroke
IVW
inverse-variance weighting
L10BF
Log10 of Bayesian factor
LD
linkage disequilibrium
LDL
low-density lipoprotein
MAP
mean arterial pressure
PP
pulse pressure
SNP
single nucleotide polymorphism
SBP
systolic blood pressure
SSBI
small subcortical brain infarcts
SVD
small vessel disease
WMH
white matter hyperintensities

Acknowledgment

The authors thank Dr. Anton J.M. de Craen (September 1966–January 2016) from the PROSPER and LLS study for his contribution to this work; the Older Australian Twins Study (OATS) participants, their supporters, and the OATS Research Team; all study participants and their relatives, general practitioners, and neurologists for their contributions; P. Veraart for help in genealogy; J. Vergeer for supervision of the laboratory work; P. Snijders for help in data collection; Dr. Anne Boland (CNG) for technical help in preparing the DNA samples for analyses; the University of Newcastle for funding; and the men and women of the Hunter region who participated in this study.

References

1.
Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007;6:611–619.
Crossref
PubMed
Google Scholar
2.
Longstreth WT Jr. Brain vascular disease: overt and covert. Stroke 2005;36:2062–2063.
Crossref
PubMed
Google Scholar
3.
Saini M, Ikram K, Hilal S, Qiu A, Venketasubramanian N, Chen C. Silent stroke: not listened to rather than silent. Stroke 2012;43:3102–3104.
Crossref
PubMed
Google Scholar
4.
Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600–606.
Crossref
PubMed
Google Scholar
5.
Bernick C, Kuller L, Dulberg C, et al. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology 2001;57:1222–1229.
Crossref
PubMed
Google Scholar
6.
Longstreth WT Jr, Dulberg C, Manolio TA, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002;33:2376–2382.
Crossref
PubMed
Google Scholar
7.
Schilling S, DeStefano AL, Sachdev PS, et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology 2013;81:292–300.
Crossref
PubMed
Google Scholar
8.
Morrison AC, Ballantyne CM, Bray M, Chambless LE, Sharrett AR, Boerwinkle E. LPL polymorphism predicts stroke risk in men. Genet Epidemiol 2002;22:233–242.
Crossref
PubMed
Google Scholar
9.
van Rijn MJ, Bos MJ, Yazdanpanah M, et al. Alpha-adducin polymorphism, atherosclerosis, and cardiovascular and cerebrovascular risk. Stroke 2006;37:2930–2934.
Crossref
PubMed
Google Scholar
10.
Song J, Kim OJ, Kim HS, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. Int J Mol Med 2010;25:819–823.
PubMed
Google Scholar
11.
Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:2066–2071.
Crossref
PubMed
Google Scholar
12.
Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008;39:1952–1959.
Crossref
PubMed
Google Scholar
13.
Serizawa M, Nabika T, Ochiai Y, et al. Association between PRKCH gene polymorphisms and subcortical silent brain infarction. Atherosclerosis 2008;199:340–345.
Crossref
PubMed
Google Scholar
14.
van Oijen M, Cheung EY, Geluk CE, et al. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study. J Neurol Neurosurg Psychiatry 2008;79:799–803.
Crossref
PubMed
Google Scholar
15.
Jeon YJ, Kim OJ, Kim SY, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol 2013;33:420–430.
Crossref
PubMed
Google Scholar
16.
Debette S, Bis JC, Fornage M, et al. Genome-wide association studies of MRI-defined brain infarcts: meta-analysis from the CHARGE Consortium. Stroke 2010;41:210–217.
Crossref
PubMed
Google Scholar
17.
Zhu YC, Dufouil C, Tzourio C, Chabriat H. Silent brain infarcts: a review of MRI diagnostic criteria. Stroke 2011;42:1140–1145.
Crossref
PubMed
Google Scholar
18.
Verhaaren BF, Debette S, Bis JC, et al. Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet 2015;8:398–409.
Crossref
PubMed
Google Scholar
19.
Genomes Project C, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56–65.
Crossref
PubMed
Google Scholar
20.
Morris AP. Transethnic meta-analysis of genomewide association studies. Genet Epidemiol 2011;35:809–822.
Crossref
PubMed
Google Scholar
21.
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190–2191.
Crossref
PubMed
Google Scholar
22.
Wang X, Chua HX, Chen P, et al. Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. Hum Mol Genet 2013;22:2303–2311.
Crossref
PubMed
Google Scholar
23.
Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet 2011;88:586–598.
Crossref
PubMed
Google Scholar
24.
Franceschini N, van Rooij FJ, Prins BP, et al. Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet 2012;91:744–753.
Crossref
PubMed
Google Scholar
25.
Beecham GW, Hamilton K, Naj AC, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet 2014;10:e1004606.
Crossref
PubMed
Google Scholar
26.
Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet 2015;16:327–350.
Crossref
PubMed
Google Scholar
27.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512–525.
Crossref
PubMed
Google Scholar
28.
Zhong H, Prentice RL. Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. Biostatistics 2008;9:621–634.
Crossref
PubMed
Google Scholar
29.
Trask TM, Ritty TM, Broekelmann T, Tisdale C, Mecham RP. N-terminal domains of fibrillin 1 and fibrillin 2 direct the formation of homodimers: a possible first step in microfibril assembly. Biochem J 1999;340:693–701.
Crossref
PubMed
Google Scholar
30.
Ratnapriya R, Zhan X, Fariss RN, et al. Rare and common variants in extracellular matrix gene Fibrillin 2 (FBN2) are associated with macular degeneration. Hum Mol Genet 2014;23:5827–5837.
Crossref
PubMed
Google Scholar
31.
Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet 2017;49:403–415.
Crossref
PubMed
Google Scholar
32.
Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J 2014;14:35–40.
Crossref
PubMed
Google Scholar
33.
Fanning JP, Wesley AJ, Wong AA, Fraser JF. Emerging spectra of silent brain infarction. Stroke 2014;45:3461–3471.
Crossref
PubMed
Google Scholar
34.
Volpe M, Rosei EA, Ambrosioni E, Leonetti G, Trimarco B, Mancia G. Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. J Hypertens 2007;25:2390–2397.
Crossref
PubMed
Google Scholar
35.
Hankey GJ, Study I, the ET. Stroke: fresh insights into causes, prevention, and treatment. Lancet Neurol 2011;10:2–3.
Crossref
PubMed
Google Scholar
36.
Tikhonoff V, Zhang H, Richart T, Staessen JA. Blood pressure as a prognostic factor after acute stroke. Lancet Neurol 2009;8:938–948.
Crossref
PubMed
Google Scholar
37.
Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med 2014;12:119.
Crossref
PubMed
Google Scholar
38.
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142–2152.
Crossref
PubMed
Google Scholar
39.
Emerging Risk Factors C, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000.
Crossref
PubMed
Google Scholar
40.
Schilling S, Tzourio C, Dufouil C, et al. Plasma lipids and cerebral small vessel disease. Neurology 2014;83:1844–1852.
Crossref
PubMed
Google Scholar
41.
Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet 2015;47:1236–1241.
Crossref
PubMed
Google Scholar
42.
Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998;29:1177–1181.
Crossref
PubMed
Google Scholar
43.
Atwood LD, Wolf PA, Heard-Costa NL, et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004;35:1609–1613.
Crossref
PubMed
Google Scholar
44.
Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928–939.
Crossref
PubMed
Google Scholar
45.
Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA. The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol 2017;27:77–85.
Crossref
PubMed
Google Scholar
46.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 92 • Number 5 • January 29, 2019
Pages: e486-e503
PubMed: 30651383

Copyright

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Publication History

Received: February 20, 2018
Accepted: October 1, 2018
Published online: January 16, 2019
Published in issue: January 29, 2019

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

CHAP: R01-AG-11101, R01-AG-030146, NIRP-14-302587. SMART: This study was supported by a grant from the Netherlands Organization for Scientific Research–Medical Sciences (project no. 904-65–095). LBC: The authors thank the LBC1936 participants and the members of the LBC1936 research team who collected and collated the phenotypic and genotypic data. The LBC1936 is supported by Age UK (Disconnected Mind Programme grant). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross-council Lifelong Health and Wellbeing Initiative (MR/K026992/1). The brain imaging was performed in the Brain Research Imaging Centre (https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging), a center in the SINAPSE Collaboration (sinapse.ac.uk) supported by the Scottish Funding Council and Chief Scientist Office. Funding from the UK Biotechnology and Biological Sciences Research Council (BBSRC) and the UK Medical Research Council is acknowledged. Genotyping was supported by a grant from the BBSRC (ref. BB/F019394/1). PROSPER: The PROSPER study was supported by an investigator-initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J.W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810). SCES and SiMES: National Medical Research Council Singapore Centre Grant NMRC/CG/013/2013. C.-Y.C. is supported by the National Medical Research Council, Singapore (CSA/033/2012), Singapore Translational Research Award (STaR) 2013. Dr. Kamran Ikram received additional funding from the Singapore Ministry of Health's National Medical Research Council (NMRC/CSA/038/2013). SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg–West Pomerania, and the network “Greifswald Approach to Individualized Medicine (GANI_MED)” funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. Whole-body MRI was supported by a joint grant from Siemens Healthineers, Erlangen, Germany, and the Federal State of Mecklenburg–West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. OATS (Older Australian Twins Study): OATS was supported by an Australian National Health and Medical Research Council (NHRMC)/Australian Research Council (ARC) Strategic Award (ID401162) and by a NHMRC grant (ID1045325). OATS was facilitated via access to the Australian Twin Registry, which is supported by the NHMRC Enabling Grant 310667. The OATS genotyping was partly supported by a Commonwealth Scientific and Industrial Research Organisation Flagship Collaboration Fund Grant. NOMAS: The Northern Manhattan Study is funded by the NIH grant “Stroke Incidence and Risk Factors in a Tri-Ethnic Region” (NINDS R01NS 29993). TASCOG: NHMRC and Heart Foundation. AGES: The study was funded by the National Institute on Aging (NIA) (N01-AG-12100), Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament), with contributions from the Intramural Research Programs at the NIA, the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Neurological Disorders and Stroke (NINDS) (Z01 HL004607-08 CE). ERF: The ERF study as a part of European Special Populations Research Network (EUROSPAN) was supported by European Commission FP6 STRP grant no. 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007–2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). Exome sequencing analysis in ERF was supported by the ZonMw grant (project 91111025). Najaf Amin is supported by the Netherlands Brain Foundation (project no. F2013[1]-28). ARIC: The Atherosclerosis Risk in Communities study was performed as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HSN268201100006C, HSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and NIH contract HHSN268200625226C. Infrastructure was partly supported by grant no. UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This project was also supported by NIH R01 grant NS087541 to M.F. FHS: This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (contracts no. N01-HC-25195 and no. HHSN268201500001I), and its contract with Affymetrix, Inc. for genotyping services (contract no. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This study was also supported by grants from the NIA (R01s AG033040, AG033193, AG054076, AG049607, AG008122, and U01-AG049505) and the NINDS (R01-NS017950, UH2 NS100605). Dr. DeCarli is supported by the Alzheimer's Disease Center (P30 AG 010129). ASPS: The research reported in this article was funded by the Austrian Science Fund (FWF) grant nos. P20545-P05, P13180, and P20545-B05, by the Austrian National Bank Anniversary Fund, P15435, and the Austrian Ministry of Science under the aegis of the EU Joint Programme–Neurodegenerative Disease Research (JPND) (jpnd.eu). LLS: The Leiden Longevity Study has received funding from the European Union's Seventh Framework Programme (FP7/2007–2011) under grant agreement no. 259679. This study was supported by a grant from the Innovation-Oriented Research Program on Genomics (SenterNovem IGE05007), the Centre for Medical Systems Biology, and the Netherlands Consortium for Healthy Ageing (grant 050-060-810), all in the framework of the Netherlands Genomics Initiative, Netherlands Organization for Scientific Research (NWO), UnileverColworth, and by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007). CHS: This CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC15103, and HHSN268200960009C and grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, R01HL085251, and R01HL130114 from the NHLBI with additional contribution from NINDS. Additional support was provided through R01AG023629 from the NIA. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Rotterdam Study: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research (NWO) Investments (no. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/NWO project no. 050-060-810. The Rotterdam Study is funded by Erasmus MC Medical Center and Erasmus MC University, Rotterdam, Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. M.A.I. is supported by an NWO Veni grant (916.13.054). The 3-City Study: The 3-City Study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Bordeaux, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques.” C.T. and S.D. have received investigator-initiated research funding from the French National Research Agency (ANR) and from the Fondation Leducq. S.D. is supported by a starting grant from the European Research Council (SEGWAY), a grant from the Joint Programme of Neurodegenerative Disease research (BRIDGET), from the European Union's Horizon 2020 research and innovation programme under grant agreements No 643417 & No 640643, and by the Initiative of Excellence of Bordeaux University. Part of the computations were performed at the Bordeaux Bioinformatics Center (CBiB), University of Bordeaux. This work was supported by the National Foundation for Alzheimer's Disease and Related Disorders, the Institut Pasteur de Lille, the Labex DISTALZ, and the Centre National de Génotypage. ADGC: The Alzheimer Disease Genetics Consortium is supported by NIH. NIH-NIA supported this work through the following grants: ADGC, U01 AG032984, RC2 AG036528; NACC, U01 AG016976; NCRAD, U24 AG021886; NIA LOAD, U24 AG026395, U24 AG026390; Banner Sun Health Research Institute, P30 AG019610; Boston University, P30 AG013846, U01 AG10483, R01 CA129769, R01 MH080295, R01 AG017173, R01 AG025259, R01AG33193; Columbia University, P50 AG008702, R37 AG015473; Duke University, P30 AG028377, AG05128; Emory University, AG025688; Group Health Research Institute, UO1 AG06781, UO1 HG004610; Indiana University, P30 AG10133; Johns Hopkins University, P50 AG005146, R01 AG020688; Massachusetts General Hospital, P50 AG005134; Mayo Clinic, P50 AG016574; Mount Sinai School of Medicine, P50 AG005138, P01 AG002219; New York University, P30 AG08051, MO1RR00096, UL1 RR029893, 5R01AG012101, 5R01AG022374, 5R01AG013616, 1RC2AG036502, 1R01AG035137; Northwestern University, P30 AG013854; Oregon Health & Science University, P30 AG008017, R01 AG026916; Rush University, P30 AG010161, R01 AG019085, R01 AG15819, R01 AG17917, R01 AG30146; TGen, R01 NS059873; University of Alabama at Birmingham, P50 AG016582, UL1RR02777; University of Arizona, R01 AG031581; University of California, Davis, P30 AG010129; University of California, Irvine, P50 AG016573, P50, P50 AG016575, P50 AG016576, P50 AG016577; University of California, Los Angeles, P50 AG016570; University of California, San Diego, P50 AG005131; University of California, San Francisco, P50 AG023501, P01 AG019724; University of Kentucky, P30 AG028383, AG05144; University of Michigan, P50 AG008671; University of Pennsylvania, P30 AG010124; University of Pittsburgh, P50 AG005133, AG030653; University of Southern California, P50 AG005142; University of Texas Southwestern, P30 AG012300; University of Miami, R01 AG027944, AG010491, AG027944, AG021547, AG019757; University of Washington, P50 AG005136; Vanderbilt University, R01 AG019085; and Washington University, P50 AG005681, P01 AG03991. The Kathleen Price Bryan Brain Bank at Duke University Medical Center is funded by NINDS grant NS39764, NIMH MH60451, and by GlaxoSmithKline. Genotyping of the TGEN2 cohort was supported by Kronos Science. The TGen series was also funded by NIA grant AG041232, the Banner Alzheimer's Foundation, The Johnnie B. Byrd Sr. Alzheimer's Institute, the Medical Research Council, and the state of Arizona and also includes samples from the following sites: Newcastle Brain Tissue Resource (funding via the Medical Research Council [MRC], local NHS trusts, and Newcastle University), MRC London Brain Bank for Neurodegenerative Diseases (funding via the Medical Research Council), South West Dementia Brain Bank (funding via numerous sources including the Higher Education Funding Council for England [HEFCE], Alzheimer's Research Trust [ART], BRACE, as well as North Bristol NHS Trust Research and Innovation Department and DeNDRoN), The Netherlands Brain Bank (funding via numerous sources including Stichting MS Research, Brain Net Europe, Hersenstichting Nederland Breinbrekend Werk, International Parkinson Fonds, Internationale Stiching Alzheimer Onderzoek), Institut de Neuropatologia, Servei Anatomia Patologica, and Universitat de Barcelona). ADNI: Funding for ADNI is through the Northern California Institute for Research and Education by grants from Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., Alzheimer's Association, Alzheimer's Drug Discovery Foundation, the Dana Foundation, and the National Institute of Biomedical Imaging and Bioengineering and NIA grants U01 AG024904, RC2 AG036535, and K01 AG030514. Support was also provided by the Alzheimer's Association (LAF, IIRG-08-89720; MAP-V, IIRG-05-14147) and the US Department of Veterans Affairs Administration, Office of Research and Development, Biomedical Laboratory Research Program. SiGN: Stroke Genetic Network (SiGN) was supported in part by award nos. U01NS069208 and R01NS100178 from NINDS. Genetics of Early-Onset Stroke (GEOS) Study was supported by the NIH Genes, Environment and Health Initiative (GEI) grant U01 HG004436, as part of the GENEVA consortium under GEI, with additional support provided by the Mid-Atlantic Nutrition and Obesity Research Center (P30 DK072488); and the Office of Research and Development, Medical Research Service, and the Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs. Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the NIH to Johns Hopkins University (contract no. HHSN268200782096C). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01 HG 004446; PI Bruce S. Weir). Study recruitment and assembly of datasets were supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control and Prevention, and by grants from NINDS and the NIH Office of Research on Women's Health (R01 NS45012, U01 NS069208-01). METASTROKE: ASGC: Australian population control data were derived from the Hunter Community Study. This research was funded by grants from the Australian National and Medical Health Research Council (NHMRC Project Grant ID: 569257), the Australian National Heart Foundation (NHF Project Grant ID: G 04S 1623), the University of Newcastle, the Gladys M Brawn Fellowship scheme, and the Vincent Fairfax Family Foundation in Australia. E.G.H. was supported by a Fellowship from the NHF and National Stroke Foundation of Australia (ID: 100071). J.M. was supported by an Australian Postgraduate Award. BRAINS: Bio-Repository of DNA in Stroke (BRAINS) is partly funded by a Senior Fellowship from the Department of Health (UK) to P.S., the Henry Smith Charity, and the UK-India Education Research Institutive (UKIERI) from the British Council. GEOS: Genetics of Early Onset Stroke (GEOS) Study, Baltimore, was supported by GEI Grant U01 HG004436, as part of the GENEVA consortium under GEI, with additional support provided by the Mid-Atlantic Nutrition and Obesity Research Center (P30 DK072488), and the Office of Research and Development, Medical Research Service, and the Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs. Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the NIH to the Johns Hopkins University (contract no. HHSN268200782096C). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01 HG 004446; PI Bruce S. Weir). Study recruitment and assembly of datasets were supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control and Prevention, and by grants from NINDS and the NIH Office of Research on Women's Health (R01 NS45012, U01 NS069208-01). HPS: Heart Protection Study (HPS) (ISRCTN48489393) was supported by the UK MRC, British Heart Foundation, Merck and Co. (manufacturers of simvastatin), and Roche Vitamins Ltd. (manufacturers of vitamins). Genotyping was supported by a grant to Oxford University and CNG from Merck and Co. J.C.H. acknowledges support from the British Heart Foundation (FS/14/55/30806). ISGS: Ischemic Stroke Genetics Study (ISGS)/Siblings With Ischemic Stroke Study (SWISS) was supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-000954-06. ISGS/SWISS used samples and clinical data from the NIH-NINDS Human Genetics Resource Center DNA and Cell Line Repository (ccr.coriell.org/ninds), human subjects protocol nos. 2003-081 and 2004-147. ISGS/SWISS used stroke-free participants from the Baltimore Longitudinal Study of Aging (BLSA) as controls. The inclusion of BLSA samples was supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-000015-50, human subjects protocol no. 2003-078. The ISGS study was funded by NIH-NINDS Grant R01 NS-42733 (J.F.M.). The SWISS study was funded by NIH-NINDS Grant R01 NS-39987 (J.F.M.). This study used the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (biowulf.nih.gov). MGH-GASROS: MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS) was supported by NINDS (U01 NS069208), the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research 0775010N, the NIH and NHLBI's STAMPEED genomics research program (R01 HL087676), and a grant from the National Center for Research Resources. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research resources. Milan: Milano–Besta Stroke Register Collection and genotyping of the Milan cases within CEDIR were supported by the Italian Ministry of Health (grant nos.: RC 2007/LR6, RC 2008/LR6; RC 2009/LR8; RC 2010/LR8; GR-2011-02347041), FP6 LSHM-CT-2007-037273 for the PROCARDIS control samples. WTCCC2: Wellcome Trust Case-Control Consortium 2 (WTCCC2) was principally funded by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z and WT084724MA). The Stroke Association provided additional support for collection of some of the St George's, London cases. The Oxford cases were collected as part of the Oxford Vascular Study, which is funded by the MRC, Stroke Association, Dunhill Medical Trust, National Institute of Health Research (NIHR), and the NIHR Biomedical Research Centre, Oxford. The Edinburgh Stroke Study was supported by the Wellcome Trust (clinician scientist award to C.L.M.S.) and the Binks Trust. Sample processing occurred in the Genetics Core Laboratory of the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. Much of the neuroimaging occurred in the Scottish Funding Council Brain Imaging Research Centre (https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging), Division of Clinical Neurosciences, University of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility, and part of the SINAPSE (Scottish Imaging Network: A Platform for Scientific Excellence) collaboration (sinapse.ac.uk), funded by the Scottish Funding Council and the Chief Scientist Office. Collection of the Munich cases and data analysis was supported by the Vascular Dementia Research Foundation. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreements no. 666881, SVDs@target (to M.D.) and no. 667375, CoSTREAM (to M.D.); the DFG as part of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy) and the CRC 1123 (B3) (to M.D.); the Corona Foundation (to M.D.); the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain) (to M.D.); the e:Med program (e:AtheroSysMed) (to M.D.) and the FP7/2007-2103 European Union project CVgenes@target (grant agreement no. Health-F2-2013-601456) (to M.D.). M.F. and A.H. acknowledge support from the BHF Centre of Research Excellence in Oxford and the Wellcome Trust core award (090532/Z/09/Z). VISP: The GWAS component of the Vitamin Intervention for Stroke Prevention (VISP) study was supported by the US National Human Genome Research Institute (NHGRI), grant U01 HG005160 (PI Michèle Sale and Bradford Worrall), as part of the Genomics and Randomized Trials Network (GARNET). Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the NIH to Johns Hopkins University. Assistance with data cleaning was provided by the GARNET Coordinating Center (U01 HG005157; PI Bruce S. Weir). Study recruitment and collection of datasets for the VISP clinical trial were supported by an investigator-initiated research grant (R01 NS34447; PI James Toole) from the US Public Health Service, NINDS, Bethesda, MD. Control data obtained through the database of genotypes and phenotypes (dbGAP) maintained and supported by the United States National Center for Biotechnology Information, US National Library of Medicine. WHI: Funding support for WHI-GARNET was provided through the NHGRI GARNET (grant no. U01 HG005152). Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GARNET Coordinating Center (U01 HG005157). Funding support for genotyping, which was performed at the Broad Institute of MIT and Harvard, was provided by the GEI (U01 HG004424). R.L. is a senior clinical investigator of FWO Flanders. F.W.A. is supported by a Dekker scholarship-Junior Staff Member 2014T001–Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre.

Authors

Affiliations & Disclosures

Ganesh Chauhan, PhD*
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hieab H.H. Adams, PhD*
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Claudia L. Satizabal, PhD*
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Joshua C. Bis, PhD*
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Alexander Teumer, PhD* https://orcid.org/0000-0002-8309-094X
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Muralidharan Sargurupremraj, PhD*
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Edith Hofer, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Stella Trompet, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Saima Hilal, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Albert Vernon Smith, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Xueqiu Jian, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Rainer Malik, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Matthew Traylor, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sara L. Pulit, PhD https://orcid.org/0000-0002-2502-3669
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Illumina, honoraria for speaking at an Illumina event at the American Society of Human Genetics (2015)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Illumina, honoraria for speaking at an Illumina event at the American Society of Human Genetics (2015) (same disclosure as above)
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Philippe Amouyel, MD
Disclosure
Scientific Advisory Boards:
1.
Alzprotect SAB, start up company
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Alzheimer's & Dementia
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Total, occupational medicine Servier, pharmaceutical company
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Inserm Lille university ANR
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Fondation Plan Alzheimer France Alzheimer
Stock/stock Options/board of Directors Compensation:
1.
Genoscreen (diagnostic start-up)
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bernard Mazoyer, MD, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yi-Cheng Zhu, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
receiving research support from National Key Technology R&D Program in the 12th Five year Plan of China. Grant number: 2011BAI08B03
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sara Kaffashian, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sabrina Schilling, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gary W. Beecham, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Beecham receives funding from the National Institutes of Health (R21HD080410, co-investigator, 2016-18; R01AG054080, PI, 2016-21; R01AG054074, MPI, 2016-21; U54AG052427, co-investigator, 2016-21; U01AG052410, MPI, 2016-21; U54NS0657, co-investigator, 2009-19; R01AG042437, subcontract PI, 2014-18; UF1AG047133, co-investigator, 2014-18; T32EY023194, co-investigator, 2013-2017; P50NS071674, co-investigator, 2010-17;U01G032984, co- investigator, 2009-2020; R01NS075764, co-investigator, 2012-17; R01AG027944, coinvestigator, 2008-2015) and the Department of Defense (W81XWH-14-1-0097, co-investigator, 2014-18).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thomas J. Montine, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Laboratory Investigation Journal of Alzheimer's Disease
Patents:
1.
NONE
Publishing Royalties:
1.
UpToDate chapter on Neuropathology
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
P50 NS062684, R01-AG031892, U01-AG046161, RF1 AG053959, UF1 AG053983, P50 AG047366
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gerard D. Schellenberg, PhD
Disclosure
Scientific Advisory Boards:
1.
Alzheimer's Association Medical Advisory Board, Society of Progressive Supranuclear Palsy External Scientific Advisory Board, United Kingdom Parkinson Disease Center, University College London Member, Steering Committee, Alzheimer?s Disease Sequence Project Co-chair, Structural Variant Work Group, Alzheimer?s Disease Sequence Project 2013-present External Advisory Committee, Mayo Clinic Rochester Udall center External Advisory Committee, University of Miami Udall Center Member, External Advisor ? Discovery Assessment Panel, Oxford Parkinson?s Disease Centre
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Alzheimer's Disease Center Directors Meeting - travel/lodging CurePSP International Research Symposium, travel/lodging Robert Katzman Memorial Lecture, University of California, San Diego, California Alzheimer?s Disease ? From Fundamental Insights to Light at the End of the Translational Tunnel, Keystone, Colorado 25th Annual Southern California Alzheimer?s Disease Research Conference, University of California Institute for Memory Impairment and Neurological Disorders, Costa Mesa, California CurePSP International Research Symposium, Baltimore, Maryland Biomarkers in Neuropsychiatric Disorders, Toronto, Canada Alzheimer?s Disease Sequence Project meeting, National Institutes of Health, Bethesda, Maryland Path to Treatment and Prevention, National Institutes of Health, Bethesda, Maryland Novartis Institutes for Biomedical Research, Inc., Novartis, Cambridge, Massachusetts McKnight Brain Institute, University of Florida, Gainesville, Florida Alzheimer?s Disease Center Directors Meeting, Washington, DC. NIA Scientific Retreat, National Institutes of Health, Bethesda, Maryland Keep Memory Alive Event Center, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV Accelerated Medicines Program Alzheimer?s Disease F2F Target Discovery and Preclinical Validation Project Meeting. ?Alzheimer?s Disease Sequencing Project ? status?, NIA/FNIH/NIH, Bethesda, MD ?Genetics of PSP and Tauopathies?, PSP/Lewy Body Disease Think-Tank. Journey from Tau to Lewy bodies. McKnight Brain Institute, University of Florida, Gainesville, Florida ?ADGC Update, NIAGADS Update? Alzheimer?s Disease Center Directors Meeting, Washington, DC. ?Update on Alzheimer?s Disease Sequence Project?, 2015 NIA Scientific Retreat, National Institutes of Health, Bethesda, Maryland ?GWAS and ?Omics Implications for Combination Therapy,? Keep Memory Alive Event Center, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV Accelerated Medicines Program Alzheimer?s Disease F2F Target Discovery and Preclinical Validation Project Meeting. ?Alzheimer?s Disease Sequencing Project ? status?, NIA/FNIH/NIH, Bethesda, MD American Association of Neuropathologists, ?Alzheimer?s Disease Genetics? Denver, CO. Fusion Conference, Personalized Medicine, ?Personalized Medicine and Neurodegenerative disorders. What does the future hold?? Tucson, AZ. CurePSP Symposium, ?Progressive supranuclear palsy genetics ? update?. La Jolla, CA Center for Public Health Genomics, Genome Sciences Seminar, University of Virginia, ?Progress in Neurodegenerative Disease Genetics?, Charlottesville, VA. March 11, 2016 Neurology Grand Rounds, Columbia University, ?Genetics of Progressive supranuclear palsy and corticobasal degeneration?, New York, NY. April 16, 2016 Alzheimer?s Disease Center Director?s meeting, Scientific Symposium: New Wine from Old Bottles; ?Alzheimer?s disease genetics: What is the progress and what is the promise?? Vancouver, British Columbia October 15, 2016 Alzheimer?s Disease Centers Director?s Meeting. ?Update on the Alzheimer?s Disease Sequence Project and other genetics programs?, Baltimore, Maryland October 27-28, 2016 2016 International Research Symposium. PSP Genetics Consortium ? Update. ?Genome- wide studies in PSP genetics?, Jersey City, New Jersey December 13, 2016 Tetra-Institute Alzheimer Research Seminar Series. ?Neurodegenerative Disease Genetics: Multiple Approaches to a Complex Problem?, Rockefeller University, New York, New York April 12, 2017 Blechman Foundation Lecture in Neurodegeneration. ?Neurodegenerative Disease Genetics: Evidence for Neuroprotection and other Mechanisms?, University of Pittsburgh, Pittsburgh, Pennsylvania April 22, 2017 Alzheimer?s Disease Centers Director?s Meeting. ?Update on the Alzheimer?s Disease Sequence Project and other genetics programs?, Boston, Massachusetts June 29, 2017 National Institute on Aging Retreat. ?Alzheimer?s Disease Genetics?, Bethesda, Maryland October 9, 2017 Niigata University, Brain Research Institute, ?Neurodegenerative Disease Genetics: Evidence for Neuroprotection and other mechanisms?, Niigata, Japan October 12, 2017 Xuan Wu Hospital, Captial Medical University, ?Neurodegenerative Disease Genetics: Evidence for Neuroprotection and other mechanisms?, Beijing, China Beijing, China October 27, 2017 2017 CurePSP International Research Symposium, Mission Bay Conference Center at UCSF, ?PSP Genetics Consortium ? Update?, San Francisco, California October 28, 2017 PSP/CBD Research Update and Family Conference, ?What We Know and Don?t Know about PSP and CBD Genetics?, San Francisco, California Februrary 12-13, 2018 Alzheimer?s Disease Sequencing Project Annual Meeting, ?Summary of work group reports 2017 for ADSP advisors and NIH leadership.?, Bethesda, Maryland March 1-2, 2018 2018 NIH Alzheimer?s Disease Research Summit, ?Genomic Center for AD?, Bethesda, Maryland March 19, 2018 Genetics of Dementia Summit ? United Kingdom, ?Affordability and feasibility of large scale genetic risk profiling: Genotype vs sequencing?, London, United Kingdom April 21, 2018 Alzheimer?s Disease Center Director?s Meeting, ?Alzheimer?s Disease Genetics Initiative.? Los Angeles, California May 15, 2018 Pathology Grand Rounds, Icahn School of Medicine, Mount Sinai, ?Tauopathy Genetics: Alzheimer?s Disease, and Progressive supranuclear palsy?, New York, New York. June 1-3, 2018 Targeting therapy of Alzheimer?s and Related Neurodegenerative Diseases, Fusion Conference. ?Tauopathy Genetics, Alzheimer?s disease, Progressivesupranulcear palsy? Nassau, Bahamas. June 6-7, 2018 Alzheimer?s Disease and Dementia Workshop. Biogen. Exploring disease mechanisms beyond Aβ and tau. ?Alzheimer?s disease genetics. Status and future goals? Boston, Massachusetts. June 11, 2018 National Institute on Aging Retreat. ?AD genetics: Gaps in our approaches and resources.? Bethesda, Maryland
Editorial Boards:
1.
Advisory Board for the Dementia Section, Journal of Neural Transmission Editorial Board, Alzheimer's Research Editorial Board, American Journal of Alzheimer?s Disease and other Dementias. Editorial Board, Neurodegenerative Diseases Editorial Board, Current Alzheimer Research Editorial Board - Pathology and Laboratory Medicine International
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Professor - University of Pennsylvania
Consultancies:
1.
(1) Biogen
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA/NIH: 1 U01AG032984-01 (Schellenberg) 04/01/15-03/29/20 2.4 calendar NIH/NIA $3,093,508 Alzheimer?s Disease Genetics Consortium The goals of this project are to: 1) assemble appropriate AD cases and control samples for gene discovery (phase 1) and replication (phase 2) to detect susceptibility genes for AD and AD-related phenotypes; 2) To combine and analyze existing and new GWAS data from a variety of datasets; 3) to perform a GWAS using Illumina Infinium II assay on the HumanHap500 Beadchip on five datasets that have not been previously studied for whole-genome analysis; 4) to perform, in three stages, follow-up for validation of interesting results. P01-AG-017586-11 (Lee) 03/01/16-02/28/21 1.2 calendar NIA/NIH $218,236 Frontotemporal Dementias: Genotypes and Phenotypes Project 2: Genetic Modifiers of tauopathies. (Schellenberg, Project PI) The goal of this renewal application is to deconstruct the genetic/genomic architecture of tauopathies with a focus on PSP and CBD, and to determine how all inherited factors contribute to the PSP/CBD/tauopathy phenotype. We will (1) use a C. elegans tauopathy model to screen for LOF alleles that suppress (protect against) the tau- induced neurodegenerative phenotype, (2) identify rare variants alter risk for PSP and CBD using whole-exome sequencing and follow-up experiments, (3) identify all MAPT region cis-acting regulatory elements and determine what gene(s) these elements regulate. ROLE: Co-Investigator 1-U24-AG041689-01 (Wang) 04/01/17-03/31/22 0.6 calendar NIA $1,000,000 The NIA Genetics of Alzheimer?s Disease Data Storage Site NIAGADS is a genetic data repository set up by the National Institute of Aging (NIA) to facilitate access by qualified investigators to genotypic data for Alzheimer's disease (AD). We propose to expand NIAGADS into a one- stop shopping data warehouse and portal for AD genetics that reflects the latest advances in genetics research and high-throughput genotyping and next-generation sequencing technologies. No overlap with the proposed project. 1UF1 AG047133-01 (Schellenberg) 06/01/14-05/13/18 (NCE) 2.16 calendar NIA/NIH $400,000 Consortium for Alzheimer?s Sequence Analysis (CASA) This U19 is a multiple PI grant to five different institutions: University of Pennsylvania, PI Gerard D. Schellenberg; Columbia University, PI Richard Mayeux; University of Miami, PI Margaret A. Pericak-Vance; Case Western Reserve University, PI Jonathan L. Haines; Boston University, PI Lindsay Farrer. Total direct costs for 2014 are $1,994,990; University of Pennsylvania direct cost for 2014 is $400,000. This project will analyze whole genome sequence and whole exome sequence data generated by the NHGRI large scale sequence centers for subjects with Alzheimer?s disease and controls who are elderly and cognitively intact. The goals are to identify single nucleotide variants and structural variants that contribute to risk or project against Alzheimer?s disease. No overlap with the current application. AG048083 Goldstein (PI) 08/15/14-06/30/19 0.12 calendar NIA/NIH $250,000 Elucidate AD genotype-phenotype relationships using genetics of human IPS cells The goal is to analyze human pluripotent stem cells (hIPSC) lines from patients carrying an APP duplication or trisomy 21(1, 2). We will use these cells to: 1) Test the hypothesis that APP and PSEN1 mutations trigger the same early events in human neurons and astrocytes leading to downstream biochemical pathology typical of AD. 2) Test the hypothesis that genes identified as risk factors in GWAS studies generate AD phenotypes and altered endocytosis, trafficking, or transport when over or underexpressed.3) Test the hypothesis that common genetic variants identified in GWAS studies act by altering gene expression. Role: collaborator U54-AG052427 (Schellenberg/Wang) 04/01/16-03/31/21 2.16 calendar NIH/NIA $1,735,875 Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD) The goal of the CGAD is to facilitate AD gene discovery by coordinating analysis of all AD-relevant data. The center will facilitate community collaboration, harmonize all AD-related genetic and phenotypic data, and coordinate primary analysis of harmonized data to identify new genetic variants that modulate AD risk. ROLE: MPI/Core A/Core B Co-Leader R01 MH109382 (PI Jordan-Sciutto, co-I Schellenberg) 09/01/16-08/31/21 0.6 calendar NIH/NIMH $425,792 Role of PERK haplotypes in HIV-Associated Neurocognitive Disorders. This study will assess the mechanisms underlying HIV- and antiretroviral drug-mediated perturbations in cellular and molecular processes that are shown to be dysregulated in age-associated neurodegenerative processes, with the aim of identifying genetic risk factors which may contribute to these perturbations within the brains of HIV positive patients. U54 NS100693 (PI Leonard Petrucelli) 09/01/16-08/31/21 1.08 calendar NINDS/NIH $281,750 (Total Direct & Indirect Institutional Costs) Center Without Walls - Tau1 Project 1, ?Identifying genes and Pathways that impact Tau Toxicity in FTD
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
CurePSP CBD Solutions
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Olafur Kjartansson, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Vilmundur Guðnason, MD, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/AG-1-2100/PI/2001-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Icelandic Heart Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David S. Knopman, MD
Disclosure
Scientific Advisory Boards:
1.
Consultant Bluefield project (frontotemporal dementia) (ongoing); Lundbeck Pharmaceuticals (Sept 2013 to August 2017); DIAN study DSMB (Sept 2013 ongoing).
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Lectures, Behavioral Neurology Conference, Hyderabad, India April 2016
Editorial Boards:
1.
Omsbudsman Neurology, currently
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Tau Rx clinical trial funded by TAURX (site PI)ended 2017 (2) A4 clinical trial partially funded by Lilly (site PI) (3) Biogen Alzheimer Study (site PI)
Research Support, Government Entities:
1.
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael E. Griswold, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data is collected by 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD). Biostatistician, 2012-2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
B. Gwen Windham, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Investigator travel expenses from ACADIA Pharmaceuticals estimated <$1000 and not related to this study. No direct compensation was included for investigator status.
Editorial Boards:
1.
Editorial board member of Journal of Gerontology: Medical Sciences
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH/NIA 5R01AG045255 principal investigator 2013-2017, NCE 2017-2018 (2) NIH/NIA 1R56AG049886 subcontract PI 2015-2017 (3) NIH/NHLBI HHSN268201700004I coinvestigator 2010-2017 (4) NIH/NHLBI/NINDS/NIA 5U01HL096917-06, Co-investigator 2010- 2017 (5) NIH/NHLBI 1R01HL126637, subcontract coinvestigator 2016-2017 (6) NIH/NHLBI 1R01HL1311136 subcontract coinvestigator 2016-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Rebecca F. Gottesman, MD
Disclosure
Scientific Advisory Boards:
1.
Member of DSMB for
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Cardiothoracic Surgery Symposium; funds for travel (reimbursement)
Editorial Boards:
1.
Neurology, Associate Editor, 2015-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Florbetapir isotope (18F-AV-45) provided for investigator-initiated research by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
Research Support, Government Entities:
1.
National Institutes of Health/ National Institute on Aging. 1R01AG040282, Principal Investigator, 9/2011-8/2021 RF1 AG050745, Multiple Principal Investigator, 4/2016-3/2021
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thomas H. Mosley, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH, HHSN268201100010C, PI, 11/2010 - 11/2016 2) NIH, U01HL096917, PI, 07/2010-04/2014 3) NIH, R01HL103695, site PI, investigator, 04/2011- 03/2015 4) NIH, R01HL105626, site PI,09/2011-06/2015 5) NIH, R01AG040282, site PI, 09/2011-05/2016 6) NIH, U01CA164975, site PI, 05/2012-04/2017 7) NIH, R01HL116900, site PI, 08/2013-07/2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Reinhold Schmidt, MD
Disclosure
Scientific Advisory Boards:
1.
Rivastigmin Patch, 2010, Novartis JSW Life Sciences 2010, Advisory Board for Dementia Trial Axon Neuroscience 2013 2014, 2015-2017 Neuroscios 2016-2017
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received travel expenses and/or honoraria for lectures from Pfizer (2004-2010), Novartis (2003-2010), Merz Austria (2005-2010) and Lundbeck Axon Neuroscience 2015 Merz Austria 2016,2017 (2004-2009) and for educational activity from Takeda 2010, Axon Neuroscience Merz, Austria 2018
Editorial Boards:
1.
Editoral board member of Clinical Neurology and Neurosurgery 2004-currently
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Pfizer 2004-2010,lectures Novartis 2003-2010,2014 lectures Merz Austria 2005-2010, lectures Lundbeck 2004-2009, lectures Takeda, 2010, teaching course Merz Austria 2009-3017
Consultancies:
1.
QPS, Austria Axon Neuroscience Neuroscios, Austria Avraham Pharmaceuticals, Isreal
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Austrian Science Fund projects P20103 and I904
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yasaman Saba, MSc
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Helena Schmidt, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Austrian Science Fund (FWF) P15454 2008-2011 Medical University Graz PHD Program BRAIN-Aging 2010-2014 Austrian National Bank Anniversary Fund P3388 2013-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Fumihiko Takeuchi, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) MEXT Japan, 16K07218, PI, 2016-2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Shuhei Yamaguchi, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Frontiers in Human Neuroscience, associate editor, 10 years
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Grant-in-Aid for Scientific Research, 18K07558, 2018-2020
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Toru Nabika, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Norihiro Kato, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kumar B. Rajan, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Professor, University of California at Davis
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH grants - R01AG051635 (principal investigator, 2016-2021), R34AT008347 (co-investigator, 2014-2017), R01AT007143 (biostatistician, 2011-2016), R01MD006173 (biostatistician, 2012-2017), R01AG030146 (biostatistician, 2012-2018), R01AG042318 (biostatistician, 2012-2018), R01NR014846 (biostatistician 2015-2020), R34MH100443 (biostatistician, 2014-2017), and R01DA039522 (biostatistician, 2015-2020)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National Institutes of Health (R01AG051635, R01AG057532).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Neelum T. Aggarwal, MD
Disclosure
Scientific Advisory Boards:
1.
1) Member - International Advisory Committee of the Saudi Alzheimer Association: Kingdom of Saudi Arabia 2) Abbvie
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
1) Non Profit - Saudi Alzheimer's Association - Non Profit Entity, Payment for Travel 2) Abbvie Payment for Advisory Services 3) Scientific Advisory Board member - MERCK - Commercial Payment for Advisory Services
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Philip L. De Jager, MD
Disclosure
Scientific Advisory Boards:
1.
1. TEVA Neuroscience, member of advisory board 2. Genzyme/Sanofi, member of advisory board 3. Celgene, member of an advisory board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Biogen IDEC: speaker honoraria Source Healthcare Analytics Pfizer Inc: speaker honoraria TEVA: speaker honoraria GSK: speaker honoraria
Editorial Boards:
1.
Journal of Neuroimmunology - member of the Editorial Board Neuroepigenetics - associate editor Multiple Sclerosis journal - member of the Editorial Board
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Investigator-initiated research grants from - Biogen - Eisai - UCB - Pfizer -Sanofi/Genzyme - Genetech - Roche
Research Support, Government Entities:
1.
R01AG042210 07/01/12 ? 06/30/17 Epidemiologic Study of TDP-43 Pathology in Aging and Dementia The major goal of the grant is to test the hypothesis that TDP-43 pathology in the aging brain is a separate disease that increases the odds of dementia and has a distinct cognitive phenotype, and specific genetic risk factors, separate from AD and other pathologies. Role: Subcontract PI R01AG043975 10/01/12 ? 08/31/17 Role of the innate Immune System in Aging and Development of Alzheimer's Disease We hypothesize that the innate immune system plays a major role in aging and the development of AD. We will study this relationship to develop treatments to prevent AD and cognitive decline with aging. Role: Collaborator R01AG043617 09/30/12 ? 08/31/17 Altered Monocyte Function in Relation to the CD33 Alzheimer?s Disease Locus The goal is to characterize the functional consequences of the CD33 locus in monocytes in (1) younger healthy subjects (2) presymptomatic older subjects, and (3) subjects with AD. We propose a multifaceted approach integrating human genetic and human immunology experiments to understand how the CD33 locus alters the state of activation in monocytes and enhances susceptibility to AD. Role: Co-Investigator Genetic Determinants for Human Sleep and Circadian Traits? CIHR 04/01/13 ? 03/31/17 The goals of this project are to identify loci associated with parameters of circadian rhythms in healthy individuals and to relate the discovered variants to differences in gene expression. Role: Subcontract PI R01 AG030146 04/01/13 ? 03/31/18 Genetic Epidemiology of Cognitive Decline in an Aging Population Sample Identify genetic determinants of cognitive decline in a healthy aging population. Role: Subcontract PI U01 AG046152 09/20/13 ? 08/31/18 Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease The overall goal of the proposed study is the discovery and preclinical validation of novel targets associated with molecular processes that lead to cognitive decline, the primary outcome of most AD trials. Role: PI R01AG017917- NIH/NIA 07/01/14 ? 06/30/19 Epidemiologic Study of Neural Reserve and Neurobiology of Aging The major goal of the continuation of MAP is to discover additional proteins associated with the slope of cognitive decline, after accounting for the effects of common pathologies. R01AG048015 04/01/15 - 03/31/20 Identifying, Validating and Targeting AD Susceptibility Networks in Monocytes The study involves implementing a novel strategy to characterize the functional consequences of genetic variants associated with Alzheimer?s disease susceptibility. R01 NS089674 (Bradshaw) 09/01/2015 ? 06/30/2019 Influence of genotype on microglia phenotype and function in PD The principal goals of the proposed project are (1) to identify, in monocytes, the component genes of networks perturbed by the PD susceptibility loci (2) to understand their functional consequences on monocyte behavior and (3) identify the genotype-to-phenotype/function connection in microglia and CNS- infiltrating macrophages.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National MS Society PI, 2008: JF2138A1
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Denis A. Evans, MD
Disclosure
Scientific Advisory Boards:
1.
McGill University,Data Safety Monitoring Board, Investigations of Naproxen Treatment Effects in Pre-Clinical Alzheimer?s Disease (INTREPAD)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Principal Investigator or Co-Investigator of NIH grants AG11101, AG030146, AG041843, AG019363, ES024700
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Co-Investigator of grant Alzheimer?s Association NIRG 302587
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bruce M. Psaty, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Zoll LifeCor, service on DSMB of a clinical trial Johnson & Johnson, service on the steering committee of the Yale Open Data Access Project
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH grants acknowledged in the paper
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jerome I. Rotter, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH - Grant
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kenneth Rice, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Oscar L. Lopez, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Grifols,Inc. and Raman Technologies
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA: P50 AG005133-29; 1P01-AG025204-04
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jiemin Liao, MA
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christopher Chen, FRCP
Disclosure
Scientific Advisory Boards:
1.
(1) Lundbeck (2) Accera
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Moleac, conference travel expenses (2) Eisai, conference travel expenses (3) Lundbeck, conference travel expenses
Editorial Boards:
1.
(1) International Journal of Stroke, member editorial board, 2005 ? present (2) Stroke, assistant editor, 2010 ? present (3) Journal of Neurology, Neurosurgery and Psychiatry, member editorial board, 2010 ? 2017 (4) Journal of the Neurological Sciences, member editorial board, 2013 ? present (6) European Journal of Stroke, member editorial board, 2016 ? present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Accera (2) Lundbeck
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) TauRx (2) Eisai (3) Nutricia (4) Lundbeck (5) Roche
Research Support, Government Entities:
1.
(1) Ministry of Health, Singapore (HSRG12May018) PI 2013-6 (2) National Medical Research Council (NMRC/CG/013/2013) PI 2013-7 (3) National Medical Research Council (NMRC/CSA/032/2011) PI 2012-7
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ching-Yu Cheng, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tien Y. Wong, MD
Disclosure
Scientific Advisory Boards:
1.
Commercial Entity: Serving advisory board with limited honoraria for Abbott, Novartis, Pfizer, Allergan, Bayer
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial Entity: Both travel or speaker honoraria through providing Consultancy services for Abbott, Novartis, Pfizer, Allergan, Bayer
Editorial Boards:
1.
Editorial board member: 2009 - date Diabetes Care 2005 - date Investigative Ophthalmology and Visual Science 2005 - date Ophthalmic Epidemiology 2009 - date Ophthalmologica 2015 ? date Journal of Hypertension 2016 ? date JAMA Ophthalmology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Commercial Entity: Consultancy services for Abbott, Novartis, Pfizer, Allergan, Bayer
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mohammad K. Ikram, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Neuroepidemiology, Editorial Board Member, 2011-2018, (2) PLoS One, Academic Editor, 2013-2017, (3) Journal of Alzheimer Disease, Academic Editor, 2016-2018, (4) European Journal of Clinical Investigation, Academic Editor, 2016-2018
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) United Nations, (2) Biogen Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Janssen Prevention Center
Research Support, Government Entities:
1.
(1) Netherlands Organization for Health Research and Development, ZonMW: 916.13.054, PI, 2012-2016, (2) European Research Council, PI, 2016-2021, (3) Joint Programme in Neurodegenerative Diseases, PI, 2014-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) the Netherlands Heart Foundation (2009B102 and 2012T008), (2) Internationaal Parkinson Fonds, (3) Internationale Stichting Alzheimer Onderzoek (#12533), (4) Alzheimer Association, (5) Alzheimer Nederland, (6) Institute for Scientific Information on Coffee
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sven J. van der Lee, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Najaf Amin, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Vincent Chouraki, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anita L. DeStefano, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. NIH/NIDDK R01 DK099269, PI, 07/01/14-05/31/19 2. NIH/NHLBI HHSN268201500001, Statistical Geneticist 02/01/02-03/31/20 3. NIH/NIA 5 R01 AG033193-04, Co-investigator 07/01/13-06/30/17 4. NIH/NIA U01 AG049505-01 Co-investigator 02/01/13-01/31/17 5. NIH/NIA R01 AG054076-01 Statistical Geneticist 09/01/16 - 05/31/21
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hugo J. Aparicio, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NIA grant R01-AG054076-02S1, trainee, 2 years
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jose R. Romero, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Dr. Romero has received speaker honoraria from Ferrer Group.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Receive support from Framingham Heart Study?s National Heart, Lung, and Blood Institute contract (N01-HC-25195) and by grants from the National Institute of Neurological Disorders and Stroke (R01 NS17950), National Institute on Aging (K23AG038444, R03 AG048180-01A1)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Pauline Maillard, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Charles DeCarli, MD
Disclosure
Scientific Advisory Boards:
1.
1) Novartis Pharmaceuticals
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1)Novartis Pharmaceuticals
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institutes of Health
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Joanna M. Wardlaw, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Medical Research Council; Stroke Association; the Fondation Leducq, the European Union Horizon 2020 project No 666881, ?SVDs@target', UK Engineering and Physical Sciences Research Council, British Heart Foundation, Alzheimer's Society, Chief Scientist Office.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
The Row Fogo Trust. ?1,496,000, 1st Apr 2001 to 31st Jul 2021. Ref No: AD.ROW4.35.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Maria del C. Valdés Hernández, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
I am a member of the World Journal of Radiology Editorial Board (ID:02666832) from 01.01.2014 until 31.12.2017 I am also an Editor of the Volume 723 of the Communications in Computer and Information Sciences (CCIS) published by Springer, as Chair of Medical Image Understanding and Analysis (MIUA) 2017.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Row Fogo Charitable Trust
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michelle Luciano, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David Liewald, BSc
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ian J. Deary, PhD
Disclosure
Scientific Advisory Boards:
1.
Member, Executive Committee and Steering Committee of the Medical Research Council Dementia Platform, 2013 to 2016. Member, Medical Research Council Cross-Board Advisory Group, 2011 to 2014. Member, Medical Research Council Population Health Sciences Group, 2011 to 2014. Member, Medical Research Council Neurosciences and Mental Health Board, 2011 to 2014.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Member, Editorial Board, Intelligence 1999 to date. Member, Editorial Board, European Journal of Personality 1996 to date. Member, Editorial Board, Personality and Individual Differences 1997 to date. Member, Editorial Advisory Board, Journal of Psychosomatic Research 1998 to date. Member, Board of Consulting Editors, Spanish Journal of Psychology 2002 to date. Member, Editorial Board, European Journal of Psychological Assessment 2005 to date. Member, Editorial Board, Psychological Science 2010 to date. Member, Editorial Board, Longitudinal and Life Course Studies, 2010 to date.
Patents:
1.
NONE
Publishing Royalties:
1.
Deary, I. J., Whalley, L. J., & Starr, J. M. (2009). A lifetime of intelligence: follow-up studies of the Scottish Mental Surveys of 1932 and 1947. Washington, DC: American Psychological Association. Matthews, G., Deary, I. J. & Whiteman, M. C. (2009). Personality traits (third edition). Cambridge: Cambridge University Press. (Translated into Romanian [2005].) Deary, I. J. (2001). Intelligence: A very short introduction. Oxford: Oxford University Press. (Translated into Arabic [2005], German [2013], Hebrew [2006], Hungarian [2003], Japanese [2004], Korean [2005], Polish [2012], Portuguese [2006] Romanian [2008], and Spanish [2004].)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Deary, I. J. Centre for Cognitive Ageing and Cognitive Epidemiology Phase 2. Medical Research Council and Biotechnology and Biological Sciences Research Council. ?4,258,772. September 2013-August 2018 (Extended to August 2019). (MR/K026992/1). Deary, I. J., Luciano, M., Prendergast, J., Wardlaw, J. M., Bastin, M., &Starr, J. M. JPND: Brain Imaging, cognition, Dementia and next generation Genomics. Medical Research Council. ?592,325. May 2016-April 2019. (MR/N027558/1.)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Deary, I. J., Starr, J. M., Wardlaw, J. M, Bastin, M. E., Ritchie, S. J., & Cox, S. R. The Disconnected Mind, Phase 4. Age UK. ?1,058,650. April 2019-March 2022. Deary, I. J., Starr, J. M., Wardlaw, J. M, & Bastin, M. E. The Disconnected Mind, Phase 3. Age UK. ?1,317,193. April 2016-March 2019. Deary, I. J., Starr, J. M., Wardlaw, J. M, & Bastin, M. E. The Disconnected Mind, Phase 3. Age UK. ?1,317,193. April 2016-March 2019.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
John M. Starr, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor-in-Chief 2013-present, Archives of Gerontology & Geriatrics
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) Medical Research Council UK, unsure of grant number but for imaging of LBC1936 cohort described in this paper, 2012-15
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mark E. Bastin, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Susana Muñoz Maniega, PhD https://orcid.org/0000-0001-5185-6384
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
UK Medical Research Council (G0701120), research fellow,2007-2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
P. Eline Slagboom, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Marian Beekman, PhD https://orcid.org/0000-0003-0585-6206
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Joris Deelen, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Alexander von Humboldt Foundation, 2017-2019
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hae-Won Uh, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
European Union?s Seventh Framework Programme (FP7-Health- F5-2012) under grant agreement number 305280 (MIMOmics)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robin Lemmens, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
FWO Flanders: Senior Clinical Investigator, 2017-2022, 1841918N FWO Flanders: Research Grant 2015-2019: basic science grant G070015N HORIZON 2020: PROOF 2017-2019 no role in this study
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Henry Brodaty, MD
Disclosure
Scientific Advisory Boards:
1.
Nutricia
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Nutricia
Editorial Boards:
1.
Aging and Mental Health, 1996 + Alzheimer's & Dementia, 2012+ Australian and New Zealand Journal of Psychiatry, Assistant Editor, 1981 - 1987. CNS Drugs, 1999 + International Psychogeriatrics, 1996 + Neurodegenerative Disease Management, 2010+
Patents:
1.
NONE
Publishing Royalties:
1.
Dementia, 2nd, 3rd and 4th (2010) editions - Hodder Arnold Physical comorbidity in dementia
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Brodaty H et al, Halting antipsychotic use in long term care (HALT Study) Aged Care Services Improvement Healthy Ageing Grant ($1.085K) (2013-2016). Brodaty H, Beattie E, Anstey KJ. Dementia Centre for Research Collaboratoin $12m (2018-2021) from NHMRC. Rowe C et al, Australian Dementia Network, Boosting Dementia Research Initiative, NHMRC, $18m (2018-2023) Brodaty H, Evaluation of BPSD Guide App and Development of BPSD App for Family Carers. Department of Social Services / Aged Care Service Improvement and Healthy Ageing Grants Fund) $224,970 (2014-2016). Brodaty H, Valenzuela M, Sachdev P, McNeil J, Maeder A, Lautenschlager N, Jorm L, Fiatarone Singh M, Anstey K, Andrews G. Maintain your Brain $6,476,015 NHMRC DRTG, (2015-2020) Sachdev P, Brodaty H, Andrews G. Risk factors, early diagnosis and effective interventions for neurocognitive disorders ($5,782,730) NHMRC Program Grant ID1093083, (2016-2020). Sachdev P, Mather K, Thalamuthu A, Armstrong N, Brodaty H. A European DNA bank for deciphering the missing heritability of Alzheimer's disease (EADB) $1,556,995 NHMRC National Institute for Dementia Research Grant (2016- 2018). Valenzuela M, Naismith S, (Brodaty H Modifying the Trajectory of Insidious Late Life Cognitive Decline with Computerised Cognitive Training NHMRC ID 1068925 $715,764 (2015-2018) Brodaty H and Shell A. Supporting GPs and Practice Nurses in the Timely Diagnosis of Dementia Alzheimers Australia grant shared with La Trobe University $177,000 (2015?2017) Brodaty H. MicroRNAs as biomarkers for Alzheimer?s disease ? comparison between Australian and Chinese populations UNSW-SJTU Collaborative Research Seed Grant $10,000. 2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Margaret J. Wright, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David Ames, MD
Disclosure
Scientific Advisory Boards:
1.
Novartis, dementia advisory board member, 2008-2011 Janssen, dementia advisory board member 2008-2010 Pfizer dementia advisory board member 2008-2011 Eli Lilly dementia advisory board Member 2012
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Yes trip to New York for prococol meeting for Prana Biotech in November 2010
Editorial Boards:
1.
Yes, 1) International Psychogeriatrics editor in chief 2003- 2011 and 2) member of Editorial board for International Journal of Geriatric Psychiatry from 1988-present and 3) Member editorial board International Reviews in Psychiatry 2011-present
Patents:
1.
NONE
Publishing Royalties:
1.
yes, Dementia 4th edn, Hodder, 2010, Guide to Psychiatry of Old Age, CUP 2010
Employment, Commercial Entity:
1.
University of Melbourne Professor of Ageing and Health and Director of National Research Institute 2007-2015
Consultancies:
1.
Prana bio member DSMB for PBT2 studies 2012-2015
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
yes ? Lilly IDENTITY study PI 2009-10, Pfizer CONCERT trial 2009-2012, Lundbeck Alzheimer trial 2010-2011 Prana HD trial 2012 2013, Amaranth trial Eli Lilly 2015-present
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Giorgio B. Boncoraglio, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jemma C. Hopewell, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
The Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, received research grants from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Schering, Solvay and The Medicines Company that are governed by University of Oxford contracts that protect its independence, and has a staff policy of not taking personal payments from industry (with reimbursement sought only for the costs of travel and accommodation to attend scientific meetings.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) British Heart Foundation (FS/14/55/30806) (2) British Heart Foundation, Centre for Research Excellence, Oxford
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ashley H. Beecham, MS
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH, R01 NS 96212, PhD Student, 08/01/14 to 05/31/19 NIH, R01 NS 29993, Biostatistician, 08/01/08 to 08/01/14 NIH, R01 NS 40807, Biostatistician, 08/01/08 to 08/01/14
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) National Multiple Sclerosis Society (2) Evelyn F. McKnight Institute
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Susan H. Blanton, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. NIH/NINDS, 7R01NS040807, co-Investigator, 2007-2017 2. NIH-NIDCD R01 DC05575, co-Investigator, 2007-2017 3. NIH-NIDCD, 5R01DC009645,co-Investigator, 2010-2018 4. NIH-NINDS/RDCRC, 2U54NS0657-12,co-Investigator, 2009-2019 5. NIH/NIDCD, P50 DC000422, Co-investigator, 2014-2018 6. NIH-NIDCD, 1R01 DC012836-05, co-Investigator, 2013-2019 7. NIH, 2R01DE011931-13, MPI, 2012-2018 8. NIH-NIDCD,2R01DC005575, co-investigator, 2017-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Clinton B. Wright, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Royalties from UpToDate website for two chapters on vascular dementia.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ralph L. Sacco, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Ed Boards: Stroke, Neuroepidemiology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Boehringer Ingelheim - Past Consultant and current institutional research support from Boehringer Ingelheim for Steering Committee of Secondary Stroke Prevention Trial with Dabigatran (RESPECT ESUS Trial)
Research Support, Government Entities:
1.
(1) NINDS, Northern Manhattan Study, PI, 1993-present R01 NS29993 (2) NINDS, Family Study, CoI, 2004-present R01 NS040807 (3) NINDS Stroke Prevention Intervention Research Program, PI, 2013-2018 (4) NCATS, Clinical Translational Science Award, PI, 2018-present (5) Florida Department of Health, Florida Stroke Registry
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Evelyn McKnight Brain Institute; American Heart Association Bugher Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Wei Wen, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. Australian National Health and Medical Research Council(NHMRC) Program Grant ID 350833; Associate Investigator, 2009-2011. 2. NHMRC Project Grant ID 510175, Chief Investigator, 2009-2011. 3. Australian Research Council (ARC) Discovery Grant ID ARC DP-0774213, Chief Investigator, 2009-2011.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anbupalam Thalamuthu, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Nicola J. Armstrong, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Elizabeth Chong, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Peter R. Schofield, PhD https://orcid.org/0000-0003-2967-9662
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Psychiatric Genetics, Editorial Board member, 2002 - present, (2) Australian and New Zealand Journal of Psychiatry, International Advisory Board member, 2011 - present, (3) International Journal of Neuropsychopharmacology, Editorial Board member, 2011 - 2016.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
This study (1) NHMRC/ARC ?Ageing Well, Ageing Productively? Research Program Grant No 401162, Chief Investigator, 2007-2011, Other research support (2) NIH Grant UF1AG032438, Site Investigator, 2014-2019, (3) NHMRC (Australia) Program Grant 1037196, Chief Investigator, 2013-2018, (4) NHMRC Project Grant, 1063960, Chief Investigator, 2014-2017, (5) NSW Health Genomics Collaborative Grants Program, Chief Investigator, 2017-2020
Research Support, Academic Entities:
1.
(1) University of New South Wales.
Research Support, Foundations and Societies:
1.
(1) Ian Potter Foundation, Chief Investigator, 2016-2017.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
John B. Kwok, PhD https://orcid.org/0000-0001-9574-6195
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
1. Dementia and Geriatric Cognitive Disorders, Editorial board, 5 years. 2. Journal of Alzheimer's disease, Associate Editor, 1 year.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. NHMRC Project grant APP1140708, Chief Investigator B, 2018 to 2021. 2. NHMRC Dementia Research Priority Round 2: JPND Call for Multinational Research Projects for Pathway Analysis across Neurodegenerative Diseases APP1151854, Chief Investigator D, 2018 to 2021. 3. NHMRC Dementia Research Team Grants APP1095127, Chief Investigator F, 2016 to 2021. 4. NHMRC Project Grant Application APP1080521, Chief Investigator F, 2015 2019.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jeroen van der Grond, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David J. Stott, MBChB, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Age and Ageing Editor in Chief 2014-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Bristol Myers Squibb
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ian Ford, PhD
Disclosure
Scientific Advisory Boards:
1.
Member of study Executive Committees for Servier, Fresinius Member of DSMBs for GSK, Medtronic, Acceleron,Medicines Company, Shire, Boston Scientific, Medimmune, Novartis
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Funding for travel to conference and study meetings from Servier.
Editorial Boards:
1.
Deputy Editor of Clinical Trials
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research grants from Servier, GSK, Actamax, Biotronik, Stealth, Pharmacosmos, Viphor Pharma
Research Support, Government Entities:
1.
Various grants from Chief Scientist Office Scotland and Medical Research Council EME NIHR HTA EU FP7 EU IMI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Wellcome Trust Arthritis Research UK British Heart Foundation Diabetes UK Juvenile Diabetes Research Foundation Stroke Association Kidney Research UK
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
J. Wouter Jukema, MD
Disclosure
Scientific Advisory Boards:
1.
JW Jukema has received research grants from and/or was speaker (with or without lecture fees) on (CME accredited) meetings sponsored by Amgen, Astellas, Anthera, Astra-Zeneca, Bayer, Biotronik, Boston Scientific,Correvio, Daiichi Sankyo, Lilly, Genzyme, Medtronic, Merck-Schering-Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi Aventis, The Medicine Company, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community Framework KP7 Programme.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Cholesterol -2010 Netherlands Heart Journal -2010 Acta Cardiologica -2010 Open Biology Journal -2010
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
JW Jukema has received research grants from and/or was speaker (with or without lecture fees) on (CME accredited) meetings sponsored by Amgen, Astellas, Anthera, Astra-Zeneca, Bayer, Biotronik, Boston Scientific,Correvio, Daiichi Sankyo, Lilly, Genzyme, Medtronic, Merck-Schering-Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi Aventis, The Medicine Company, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community Framework KP7 Programme.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Meike W. Vernooij, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) research fellowship from the Erasmus MC University Medical Center, Rotterdam, the Netherlands (2) a Netherlands Organization of Scientific Research (NWO)/ZonMW clinical fellowship (90700435)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Albert Hofman, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editor Eur J Epidemiol from 2000 onwards
Patents:
1.
NONE
Publishing Royalties:
1.
Royalties two Dutch books on epidemiology: Grondslagen der Epidemiologie, Elsevier 2008 Klinische Epidemiologie Elsevier 2000 Investigating neurological disease, Cambridge University press 1996
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
André G. Uitterlinden, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Aad van der Lugt, MD
Disclosure
Scientific Advisory Boards:
1.
(1) Siemens
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial Board -Neurovascular Imaging -Quantitative Imaging In Medicine and Surgery
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Commercial entity: Stryker Inc
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
My institution (Erasmus MC) has received research support from GE Healthcare My institution (Erasmus MC) has received research support from Stryker, Penumbra and Medtronic for the conduct of randomized trials of endovascular treatment for acute ischemic stroke.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
My institution (Erasmus MC) has received grants from the 1) Dutch Heart Foundation, 2) Dutch Brain Foundation and 3) EU (H2020)for the CONTRAST studies
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Katharina Wittfeld, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hans J. Grabe, MD https://orcid.org/0000-0003-3684-4208
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Fresenius Medical Care
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Janssen
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Fresenius Medical Care
Research Support, Government Entities:
1.
BMBF, DFG
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Damp
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Norbert Hosten, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bettina von Sarnowski, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Uwe Völker, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
BMBF, DFG, EU
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christopher Levi, BMedSci, FRACP
Disclosure
Scientific Advisory Boards:
1.
1. Apixaban Scientific Advisory Board - Pfizer 2. National Stroke Foundation (Australia) Research Advisory Committee & Dabigitran Treatment following TIA and minor stroke (DATAS) 2 DSMB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
I have received travel expenses and/or honoraira for lectures or educational activities not funded by industry
Editorial Boards:
1.
Editorial Board Member - Medical journal of Australia 2016 ff
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Expert External Reviewer - Stroke and Neurology Service, The Alfred Hospital, Melbourne. 2012
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHMRC Practitioner Fellowship 2013-21 ongoing NHMRC Project, Program and Partnership Grants 2000-2021 ongoing
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National Stroke Foundation, Australia
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jordi Jimenez-Conde, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
IMIM-Hospital del Mar, Adjunct Neurologist
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NINDS/NI, U01NS069208, Center PI,2011-14, (2) ISCIII/Spanish Government Grants, PI10/02064, PI, 2011-13,(3)ISCIII/Spanish Government Grants, PI15/00451, PI, 2015-18,
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Pankaj Sharma, MD, PhD
Disclosure
Scientific Advisory Boards:
1.
Bohringer 2009 & 2013 advisory board member 2013-14 Bayer advisory board member
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
J Royal Soc Medicine Cardiovascular Disease Editor in Chief
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Cathie L.M. Sudlow, FRCP(Ed)
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Cancer Research UK Brain cancer Centre of Excellence (Co-I), ?3 Million 2018-2023 (2) Health Data Research UK Scottish Substantive Site Award (PI), ?5 million, 2018-2023 (3) Health Data Research UK: UKRI/Rutherford HRDUK Fellowships (PI), ?1.2 million, 2018-2021 (4) UK MRC and Wellcome Trust: UK Biobank programme renewal, ?35 million, 2010-2017 (co-I) (5) UK MRC, Dementias Platform UK programme grant, ?12 million, 2014-2019 (co-I) (6) UK MRC, Wellcome Trust, British Heart Foundation: UK Biobank imaging study, ?43 million, 2013-2022 (co-I) (7) European Union Innovative Medicines Initiative Horizon 2020 programme, ROADMAP (real world outcomes in Alzheimer's Disease), 8 million euros (about 50% EU, 50% EFPIA pharma company partners), 2016-2018 (co-I) (8) UK MRC: Mental Health Data Pathfinder Award (co-I), 2018-2021, ?1.3 million (9) MRC: Environment-wide association studies (co-I), 2017-2020, ?471K
Research Support, Academic Entities:
1.
(1) British Heart Foundation, 2012-2017, RESTART trial of antiplatelet treatment in ICH ( co-I)
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jonathan Rosand, MD
Disclosure
Scientific Advisory Boards:
1.
Pfizer, DSMB
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Lancet Neurology, editorial board member Stroke, editorial board member
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Boehringer Ingelheim, 2017
View all articles by this author
Daniel Woo, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Stroke- Section Editor, 2015-Present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH Funding: NS36695 (PI: 1998-Current); NS30678 (CoI: 1998-Current). NS93870 (PI: 2010-Current).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
John W. Cole, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Book entitled: Stroke Essentials for Primary Care, Alway, David; Cole, John Walden (Eds., 2009, Springer, ISBN: 978-1-934115-01-5
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
American Heart Association/Bayer Pharmaceuticals Cole Role: PI Grant #17IBDG33700328 The Genetics and Biomarkers of Small Vessel Stroke.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
James F. Meschia, MD
Disclosure
Scientific Advisory Boards:
1.
I Chair the data safety monitoring board for the NINDS NeuroNEXT clinical trail network.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
I serve as an Associate Editor for the European Journal of Neurology and the Neurology Section Editor for the Mayo Clinic Proceedings.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Meschia receives support from the NINDS for efforts devoted to serving as co-Principal Investigator on the CREST-2 trial.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Agnieszka Slowik, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Vincent Thijs, MD https://orcid.org/0000-0002-6614-8417
Disclosure
Scientific Advisory Boards:
1.
(1) Bayer advisory board (2) Pfizer/BMS advisory board (3) Medtronic advisory board
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Medtronic (2) Boehringer Ingelheim (3) Pfizer (4) Bayer (5) Astra Zeneca
Editorial Boards:
1.
Acta Neurologica Belgica, Associate Editor, ongoing Stroke Editorial board member, ongoing European Journal of Emergency Medicine, Editorial Board member, ongoing European Stroke Journal, Editorial Board member, ongoing International Journal of Stroke, Editorial board member, ongoing
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Boehringer Ingelheim (2) Pfizer (3) Bayer (4) Astra Zeneca (5) Medtronic
Speakers' Bureaus:
1.
Pfizer Inc Boehringer Ingelheim Medtronic Bayer
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Medtronic, Inc., Pfizer Inc., AstraZeneca, Boehringer Ingelheim, Astra Zeneca
Research Support, Government Entities:
1.
NHMRC
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Arne Lindgren, MD
Disclosure
Scientific Advisory Boards:
1.
(1)Astra Zeneca (2)Bristol-Myers Squibb (3)Boehringer Ingelheim (4)Sanofi (5)Pfizer (6)Bayer (7)Reneuron
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1)Astra Zeneca, speaker honoraria (2)Bristol-Myers Squibb, speaker honoraria (3)Boehringer Ingelheim, speaker honoraria (4)Sanofi, speaker honoraria (5)Pfizer, speaker honoraria, travel (6)Bayer, speaker honoraria
Editorial Boards:
1.
(1) Neurologi i Sverige. Editorial advisory board member.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Olle Melander, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1. European Research Council StG-282255 2012-2016, 2. Swedish Research Council Dnr 2014-2319 2015-2018, 3. Swedish Heart-Lung Foundtation Dnr. 20150307 2016-2018, 4. Wallenberg Clinical Scholar 2016-2020, 5. G?ran Gustafssons Foundation 2016-2018
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Raji P. Grewal, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS UO1 NS069208, 07/01/2011 to 07/01/2014, role Subrecipient PI.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tatjana Rundek, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
1. Stroke, assistant editor, 2013- 2. Neurology, editorial board member, 2010-2017 3. Cerebrovascular Disease, editorial board member, 2010- 4. Journal of Ultrasound in Medicine, editorial board member, 2010-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS R01 NS040807 (PI), 2016- NIMHD R01 MD012467 (PI), 2017- NINDS R37 NS 029993 (Co-Investigator), 2000- NINDS K24 NS 062737 (Principal Investigator), 2009-2016 NINDS R01 NS 065114 (Principal Investigator), 1010-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Evelin F. McKnight Brain Institute
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kathy Rexrode, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Invited speaker for the International Magnesium conference in Rome 2017 ($500 to cover travel)
Editorial Boards:
1.
Neuology and JAMA Internal Medicine editorial advisory boards
Patents:
1.
NONE
Publishing Royalties:
1.
Editor, Women and Health 2012 (2016 <600$)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Quincy Bioscience- review of safety reports on over the counter supplements
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHLBI R01-
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Scientific Board for Tegterra/ Inside Tracker. Stock options only with 0$ worth (no stock currently available- not publicly traded- I think unlikely to be ever stock)
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Peter M. Rothwell, MD
Disclosure
Scientific Advisory Boards:
1.
Bayer - Executive Committee of ARRIVE Trial - 2006 onwards Servier - Executive Committee of PERFORM trial - 2005 -2010 Pfizer - IDMC if Rocket-AF Trial - 2006 - 2009 Biotronic - Executive Committee of device trial - 2005 - 2011
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
I don't keep a record. Certainly had travel expenses paid by Sanofi-Aventis, Servier, Astra-Zeneca and Bayer in past. However, nothing relevant to this manuscript.
Editorial Boards:
1.
Editorial Board - Lancet Neurology, International Journal of Stroke
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Donna K. Arnett, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH R01HL055673 PI 2016-2019 NIH R01HL091357 PI 2018-2020 NIH U54HG007479 Co-I 2018-2023 NIH R01HL104135 PI 2016-2018 NIH U01HL107437 Co-I 2011-2017
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christina Jern, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) The Sahlgrenska Academy and the Sahlgrenska University, ALFGBG-148861, PI, 2011-2014 (2) The Swedish Medical Research Council, K2014-64X-14605-12- 5, PI, 2014-2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) The Swedish Heart Lung Foundation (2) The Swedish Stroke Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Julie A. Johnson, PharmD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of American Hear Association, Editorial Board, 2012-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH-NINDS, R01 NS073346
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Oscar R. Benavente, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Honorarium from, Bayer, Boehringer Ingelheim, Pfizer
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant for Otsuka
Speakers' Bureaus:
1.
Bayer
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Funded by NIH-NINDS
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sylvia Wasssertheil-Smoller, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jin-Moo Lee, MD, PhD
Disclosure
Scientific Advisory Boards:
1.
DSMB member for CATCH trial: A Multicenter, Open-Label, Phase 2a Proof-of-Concept Study to Evaluate the Administration of CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage; sponsored by AegisCN
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS R01NS084028 (PI), R01NS085419 (PI), R01NS094692 (PI), R21AG05533301 (PI).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Foundation for Barnes-Jewish Hospital (Landau Fund, Lillian Strauss Fund)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Quenna Wong, MS
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH NINDS, HHSN268201200008I, analyst, 2013-2014 (2) NIH NHLBI, HHSN268201300005C, analyst, 2014-2015
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Braxton D. Mitchell, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Frontiers in Neurology (Review editor, Stroke), 2017- (2) Current Genetic Medicine Reports (Section editor, Cardiovascular Genetics), 2017
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. NIH P30DK072488,Co-Director, 2011 - 2019 2. NIH U01NS069208, Co-Investigator, 2010 - 2015 3. NIH R01NS073346, Co-Investigator, 2011 ? 2015 4. NIH R01NS086905, Co-Investigator, 2016 ? 2020 5. R01 NS100178, MPI, 2017-2022 6. R01 NS105150, MPI, 2017-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Stephen S. Rich, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH, DP3-DK111906, PI, 2016-2021 NIH, R01-HD74368, co-Investigator, 2013-2019 NIH, UC4-DK095300, co-Investigator, 2014-2019 NIH, R01-HL120393, MPI, 2014-2018 NIH, R01-AT0008621, co_investigator, 2015-2020 NIH, R01-AR047988, co-Investigator, 2016-2021 NIH, R01-HL131565, co-Investigator, 2016-2021
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Patrick F. McArdle, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Regeneron
Research Support, Government Entities:
1.
NINDS (Kittner/Mitchell) 1/15/2018-12/31/22 R01NS105150-01 Genetics of Early-Onset Ischemic Stroke Consortium Role: Co-Investigator NINDS (Mitchell) 6/1/2017-2/28/22 R01NS100178-01A1 Role: Co-Investigator R01NS086905 7/1/2015-4/30/18 MRI-GENetics Interface Exploration (MRI-GENIE) Study (Supplement) Role: Supplement PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mirjam I. Geerlings, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's disease, Associate Editor, 2012- 2013
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Netherlands Organisation for Scientific Research (NWO), project No. 917-66-311, principal investigator, 2006-2012
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yolanda van der Graaf, MD, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Vertex Pharmaceuticals, Senior Director, 2015-present
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Paul I.W. de Bakker, PhD https://orcid.org/0000-0001-7735-7858
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Vertex Pharmaceuticals, Senior Director, 2015-present
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Folkert W. Asselbergs, MD https://orcid.org/0000-0002-1692-8669
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Velandai Srikanth, FRACP
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) International Journal of Stroke, 2013, (2) Frontiers of Neurology, 2014
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Health and Medical Research Council of Australia, grants 403000, 491109, 606544' years 2006 till present.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Russell Thomson, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) nbn? (2) Birdlife Australia (3) Mission Australia (4) Cooper Vision (5) Australian Valuations
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Department of Education and Training
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Rebekah McWhirter, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NHMRC Project Grant 1060187, CI, 2014 - 2017
Research Support, Academic Entities:
1.
(1) Faculty of Law, University of Tasmania (2) Menzies School of Health Research, Charles Darwin University
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Chris Moran, FRACP
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Australasian Journal of Ageing, Associate Editor, 2018, ongoing. No compensation.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHMRC/ARC Dementia Fellowship, 2016-2019
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1)Royal Australasian College of Physicians, (2) Mason Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michele Callisaya, PhD
Disclosure
Scientific Advisory Boards:
1.
National Health and Medical Research Council fellowship committee
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer Disease, Associate Editor 2016-18
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHRMC Boosting Dementia Leadership fellowship APP1135761
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thanh Phan, FRACP
Disclosure
Scientific Advisory Boards:
1.
Advisory Board for Genzyme
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker honoraria for Genzyme, Boehringer Ingelheim, Bayer, Pfizer, BMS
Editorial Boards:
1.
Associate Editor, Frontiers in Neurology (Stroke subsection) and PLOS ONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Advisory Board for Genzyme
Speakers' Bureaus:
1.
Genzyme; Bayer; Boehringer Ingelheim; Pfizer, BMS
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Loes C.A. Rutten-Jacobs, PhD https://orcid.org/0000-0003-3223-885X
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Steve Bevan, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christophe Tzourio, MD, PhD https://orcid.org/0000-0002-6517-2984
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Member editorial board of Neuroepidemiology (2005-)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Agence Nationale de la Recherche
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Karen A. Mather, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The studies were supported by a NHMRC Program Grant 350833. I have been supported by the NHMRC Capacity Building Grant 568940 (2012-13).
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
I was supported by an Alzheimer's Australia Dementia Research Foundation Postdoctoral Fellowship (2013-14).
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Perminder S. Sachdev, MD
Disclosure
Scientific Advisory Boards:
1.
Member of the Scientific Program Committee of the Alzheimer's Association (not for profit; no remuneration)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel support from the Alzheimer's Association to attend the Scientific Program Committee and the Alzheimer's Association International Conference 2018 in Chicago. Travel support to attend a collaborators' meeting in Renji Hospital, Shanghai.
Editorial Boards:
1.
American Journal of Geriatric Psychiatry, Editorial Board, 2008-17 Acta Neuropsychiatrica, Editorial Board, 2006-11 Neuropsychiatric Disorders and Treatment, 2005-11 Current Opinion in Psychiatry, Section editor, 2008- continuing International Psychogeriatrics editorial board 2017 - continuing.
Patents:
1.
NONE
Publishing Royalties:
1.
The Yipping Tiger and Other tales from the Neuropsychiatry clinic, University of New South Wales Press, 2009 Secondary Schizophrenia, Cambridge University Press, 2010 Akathisia and Restless legs, Cambridge University Press, 1993. The Ageing Brain, Wiley, 2000. A migrant's musings., Amazon, 2017.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Series of talks on Alzheimer's disease in China, sponsored by Elsevier Health Science, China (2015) Talk in 2011 to the Queensland Neuropsychiatry Group (sponsored by Eli Lilly). Symposium on Deep Brain Stimulation, sponsored by Boston Scientific. Talk to Alzheimer's Master Class 2009 (sponsored by Pfizer) Lectures to Universities and conferences on a regular basis - all non-profit and without payment.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NHMRC Boosting Dementia Initiative Grant - Rowe C, Sachdev P, et al. The Australian Dementia Network. 2018-23 NIH grant (RG-172507) Cohort Studies of Memory in an International Consortium (COSMIC). 2017-22. NHMRC Capacity Building Grant ? ID No 568940 ? Sachdev P, Brodaty H, Andrews G, Lord S. Prevention and management of mental disorders in Older Australians. 5 years ? 2009- 2013. UNSW Goldstar ? ID No. 568785 ? Sachdev P, Easteal S, Wen W. Neurocognitive and physical health in extreme old age: Sydney Centenarian Study ? 1 year ? 2009. NHMRC Program Grant ? ID No. 568969 ? Sachdev P, Brodaty H, Andrews G. The prevention early detection and effective management of neurocognitive disorders in the elderly. 2010-2014. NHMRC Project Grant ? ID No. 630592 ? Sachdev P, Richmond R, Kochan N, Wen W, Crawford J. A cognitive and neuroimaging study of exceptionally old individuals: Sydney Centenarian Study. 3 years - 2010-2012. Department of Health & Ageing. Dementia Collaborative Research Centre ? Assessment and Better Care, Centre Funding ? 2010-2013 - (4 years) (Brodaty / Sachdev / Broe / Draper). Department of Innovation, Industry, Science & Research (DIISR). Collaborative Research Networks Grant - ? 2011-2013 (3 years) (Lead CI/Institution: Prof Annabelle Duncan/University of New England (UNE); Kelly B - UoN; Llewellyn G ? USyd; Pitts M ? LaTrobe; Moran G - UNSW); Sachdev P (AI). CSIRO Flagship Project Grant. SNP and CNV analysis of discordant neuropsychiatric and brain imaging traits in twins from the Older Australians Twin Study (OATS). ? 2011 - (1 year) (Sachdev / Mather / Dusing). NIH grant no 1RF1AG057531, 2017-21.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Pacific Alzheimer Research Foundation (PARF) Operating Grant ? ID No. PARF OP06-04-Beg. Improving sensitivity of early detection of Alzheimer?s disease (AD) via multi- dimensional analysis of longitudinal MRI scans. 3 years - 2007-2009.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Occasional expert opinion on medicolegal matters not related to the present study.
View all articles by this author
Cornelia M. van Duijn, PhD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bradford B. Worrall, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neurology: Associate Editor 1 July 2009 - September 2015; Deputy Editor October 2015 - present Seminars in Neurology Editorial Board 2006-2014
Patents:
1.
NONE
Publishing Royalties:
1.
Chapter Author for Merritt's Neurology editions 10, 11, and 12.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
AegisCN, LLC/Duke Clinical Research Institute - Serving as a site for phase II clinical trial titled
Research Support, Government Entities:
1.
NINDS/NIH ? U24 NS107222 (co-Principal Investigator) 2018-2023 NIH/NCATS ? U54 TR002586 (co-Principal Investigator KL2) 2018-2023 NINDS/NIH - R21 NS106480 (Principal Investigator) 2018-2020 NINDS/NIH - R01 NS 069763 (co-investigator) 2010-2017 NINDS/NIH ? U-01 NS069208 (co-Principal Investigator) 2010-2015 NHGRI/NIH ? U-01 HG005160 (co-Principal Investigator) 2009-2014
Research Support, Academic Entities:
1.
University of Virginia - CENTERS OF EXCELLENCE CLINICAL RESEARCH GRANT SUPPORT - The UVA BRAIN AND AORTIC ANEURYSM SCREENING (BAAS) study - Principal Investigator 10/13-4/17
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Martin Dichgans, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Bayer Vital, funding for travel to speak (2) Boehringer Ingelheim,funding for travel to speak (3) Daiichi-Sankyo,funding for travel to speak (4) 4SC Discovery GmbH,funding for travel to speak (5) Pfizer Pharma GmbH,funding for travel to speak
Editorial Boards:
1.
(1) Stroke the International Journal of Stroke, Section Editor Stroke (AHA) 2006 - 2010 and 2015- present, (2) Genetics Intern. J. Stroke, Section Editor, 2013-2016 (WSO) (3) Journal of Neurochemistry, Handling Editor, 2011-2016 (4) Frontiers in Stroke, Associate Editor, 2010- present (5) Annals of Neurology, Editorial Board Member, 2017- present (6) European Stroke Journal, Editor, 2016- present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Bayer Vital, (2) Boehringer Ingelheim, (3)4SC Discovery GmbH, (4) Daiichi Sankyo (5) EVER Neuro Pharma
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1)European Union (EU-Horizon 2020,GA No. 667375),PI, 12/2015-11/2020 (2) European Union (EU-Horizon 2020,GA No. 666881) Coordinator, 01/2016-12/2020 (3) German Federal Ministry of Education and Research (BMBF), principal investigator,01ZX1313F,12/13-11/16 (4) DFG, EXC 1010/1, principal investigator, 01/2013- 12/2018 (5) DFG, SFB 1123/1, B03, principal investigator, 10/2014- 07/2022 (6) DFG, GZ: DI 722/13-1, principal investigator, 01/2017- 12/2019 (7) Fondation Leducq, Grant no.12 CVD 01, principal investigator, 10/2012-09/2018
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Vascular Dementia Research Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Steven J. Kittner, MD
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial Board, Neuroepidemiology, 2000- present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS: R01NS100178, Co-PI, 2017-2022 NINDS: R01NS105150, Co-PI, 2017-2022 NINDS: 2U01NS036695, Site PI, 2016-2021 NINDS: R01NS086905, Site PI, 2015-2020 NINDS: R01NS100417, Site PI, 2017-2022
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hugh S. Markus, FMedSci
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Section editor International Journal of stroke Editorial board Clin Neurology and Neurosurgery and BMC Medicine Associate Editor Frontiers in Neurology
Patents:
1.
NONE
Publishing Royalties:
1.
Stroke Medicine OUP. 2016
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Astra Zeneca >$1000
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Reimbursement from Astra Zeneca for teaching session to employees
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
MRC experimental medicine grant 2016-20 NIHR Senior Investigator and NIHR HTA Grant
Research Support, Academic Entities:
1.
Stroke Association, EU, Wellcome Trust, The British Heart Foundation, Alzheimer Research UK for peer reviewed research grants
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Mohammad A. Ikram, MD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Myriam Fornage, PhD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Lenore J. Launer, PhD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institute on Aging Intramural Research Program, Employee, 1999-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Sudha Seshadri, MD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor since 2005. Stroke: Editorial Board since 2010. Neurology: Editorial Board since 2011.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIA AG033040, AG049505, AG033193, AG049607, AG054076, AG052409 NINDS NS017950, NS100605
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
W.T. Longstreth Jr, MD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Dr. Longstreth is a co-investigator on several NIH-fundedstudies.
Research Support, Government Entities:
1.
NIA AG033040, AG049505, AG033193, AG049607, AG054076, AG052409 NINDS NS017950, NS100605
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Stéphanie Debette, MD‡
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial board of Stroke, International Journal of Stroke
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
French National Research Agency (ANR), EU Joint Programme-Neurodegenerative Disease Research (JPND), EuropeanUnion?s Horizon 2020 research and innovation programmeunder grant agreement No 643417 (JPND - BRIDGET), No640643 (ERC - SEGWAY), and No 667375 (COSTREAM)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Leducq Foundation (member of Transatlantic Network of Excellence), Fondation Claude Pompidou
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
on behalf of the Stroke Genetics Network (SiGN), the International Stroke Genetics Consortium (ISGC), METASTROKE, Alzheimer's Disease Genetics Consortium (ADGC), and the Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium

Notes

Correspondence Dr. Debette [email protected] or Dr. Longstreth [email protected]
*
These authors contributed equally to this work.
‡
These authors jointly supervised this work.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Author affiliations appear on pages e496–e498.
Coinvestigators are listed at links.lww.com/WNL/A800.
The Article Processing Charge was funded by The University of Edinburgh.

Author Contributions

Drs. Chauhan, Adams, Satizabal, Bis, Teumer, and Sargurupremraj contributed equally to this work. Drs. Ikram, Fornage, Launer, Seshadri, Longstreth, and Debette jointly supervised this work. Study design/conception: Drs. Schofield, Tzourio, Schellenberg, Kato, Psaty, Slagboom, Stott, Ford, Jukema, Fornage, Seshadri, Longstreth, and Debette. Statistical analysis: Drs. Schofield, Chauhan, Sargurupremraj, Satizabal, Teumer, Hofer, Trompet, Hilal, Smith, Malik, Saba, Takeuchi, Rice, van der Lee, Luciano, Deelen, Uh, Beecham, Thalamuthu, Armstrong, Grabe, and McWhirter. Sample/phenotype contribution: Drs. Phan, Schofield, Kwok, Hilal, Malik, Traylor, Tzourio, Schellenberg, Knopman, Griswold, Windham, Mosley, Schmidt, Schmidt, Yamaguchi, Nabika, Psaty, Lopez, Chen, Cheng, Amin, Aparicio, DeCarli, del Carmen Valdés Hernández, Deary, Starr, Bastin, Maniega, Beekman, Lemmens, Brodaty, Wright, Boncoraglio, Hopewell, Blanton, Wright, Sacco, Wen, Chong, van der Grond, Stott, Ford, Jukema, van der Lugt, Wittfeld, Grabe, Hosten, von Sarnowski, Völker, Jimenez-Conde, Sharma, Rosand, Cole, Thijs, Lindgren, Rundek, Rexrode, Arnett, Johnson, Benavente, Wasssertheil-Smoller, Lee, Mitchell, McArdle, Moran, Callisaya, Mather, Sachdev, van Duijn, Dichgans, Kittner, Markus, Launer, Longstreth, and Debette. Drafting the article: Drs. Chauhan, Seshadri, Longstreth, and Debette. Critical revision of the article: Drs. Chauhan, Satizabal, Teumer, Hofer, Trompet, Malik, Traylor, Tzourio, Windham, Mosley, Schmidt, Yamaguchi, Kato, Psaty, Rice, Lopez, Chen, Aparicio, DeCarli, del Carmen Valdés Hernández, Luciano, Deary, Bastin, Maniega, Slagboom, Beekman, Deelen, Uh, Lemmens, Wright, Boncoraglio, Wen, Thalamuthu, Armstrong, van der Grond, Stott, Ford, Jukema, van der Lugt, Wittfeld, Grabe, Hosten, von Sarnowski, Jimenez-Conde, Rosand, Thijs, Lindgren, Rundek, Lee, Mitchell, Rich, Geerlings, McWhirter, Callisaya, Mather, Sachdev, Dichgans, Kittner, Markus, Launer, Seshadri, Longstreth, Debette, Adams, Bis, Jian, Pulit, Amouyel, Mazoyer, Zhu, Sargurupremraj, Kaffashian, Beecham, Montine, Kjartansson, Gudnason, Gottesman, Rajan, Aggarwal, De Jager, Evans, Rotter, Liao, Wong, Ikram, Chouraki, DeStefano, Romero, Maillard, Wardlaw, Ames, Vernooij, Hofman, Uitterlinden, Levi, Sudlow, Woo, Meschia, Slowik, Melander, Grewal, Rothwell, Jern, van der Graaf, de Bakker, Asselbergs, Thomson, Rutten-Jacobs, Bevan, Worrall, Ikram, Smith, and Schilling. Funding: Drs. Schofield, Trompet, Tzourio, Schellenberg, Mosley, Schmidt, Schmidt, Psaty, Cheng, Deary, Starr, Bastin, Slagboom, Wright, Wen, Stott, Ford, Jukema, Völker, Rosand, Lindgren, Johnson, Srikanth, Mather, Sachdev, Markus, Fornage, Seshadri, Longstreth, and Debette. Supervision: Drs. Kwok, Schellenberg, Psaty, Amin, Slagboom, Wen, Jukema, Grabe, Mather, Sachdev, van Duijn, Fornage, Seshadri, Longstreth, and Debette. Final approval of the version to be published: Drs. Satizabal, Teumer, Hofer, Trompet, Hilal, Malik, Traylor, Tzourio, Schellenberg, Griswold, Windham, Mosley, Schmidt, Schmidt, Takeuchi, Nabika, Kato, Psaty, Rice, Lopez, Chen, Cheng, van der Lee, Amin, Aparicio, DeCarli, del Carmen Valdés Hernández, Luciano, Deary, Starr, Bastin, Maniega, Slagboom, Beekman, Deelen, Uh, Lemmens, Brodaty, Wright, Boncoraglio, Hopewell, Beecham, Wen, Thalamuthu, Armstrong, Chong, van der Grond, Stott, Ford, Jukema, van der Lugt, Wittfeld, Grabe, Hosten, von Sarnowski, Völker, Jimenez-Conde, Rosand, Cole, Thijs, Lindgren, Rundek, Rexrode, Johnson, Wasssertheil-Smoller, Wong, Mitchell, Rich, McArdle, Geerlings, McWhirter, Moran, Callisaya, Mather, Sachdev, van Duijn, Dichgans, Markus, Fornage, Launer, Seshadri, Longstreth, Debette, Kittner, Adams, Bis, Jian, Pulit, Amouyel, Mazoyer, Zhu, Sargurupremraj, Kaffashian, Beecham, Montine, Kjartansson, Gudnason, Gottesman, Rajan, Aggarwal, De Jager, Evans, Rotter, Liao, Wong, Ikram, Chouraki, DeStefano, Romero, Maillard, Wardlaw, Ames, Vernooij, Hofman, Uitterlinden, Levi, Sudlow, Woo, Meschia, Slowik, Melander, Grewal, Rothwell, Jern, der Graaf, de Bakker, Asselbergs, Thomson, Rutten-Jacobs, Bevan, Worrall, Ikram, and Smith.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Sailimai Man,
    • Yining Zu,
    • Xiaochen Yang,
    • Yuhan Deng,
    • Dan Shen,
    • Yuan Ma,
    • Jingzhu Fu,
    • Jing Du,
    • Canqing Yu,
    • Jun Lv,
    • Gang Li,
    • Bo Wang,
    • Liming Li,
    Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults, Journal of the American College of Cardiology, (2025).https://doi.org/10.1016/j.jacc.2025.02.032
    Crossref
    • Seth S. Martin,
    • Aaron W. Aday,
    • Norrina B. Allen,
    • Zaid I. Almarzooq,
    • Cheryl A.M. Anderson,
    • Pankaj Arora,
    • Christy L. Avery,
    • Carissa M. Baker-Smith,
    • Nisha Bansal,
    • Andrea Z. Beaton,
    • Yvonne Commodore-Mensah,
    • Maria E. Currie,
    • Mitchell S.V. Elkind,
    • Wenjun Fan,
    • Giuliano Generoso,
    • Bethany Barone Gibbs,
    • Debra G. Heard,
    • Swapnil Hiremath,
    • Michelle C. Johansen,
    • Dhruv S. Kazi,
    • Darae Ko,
    • Michelle H. Leppert,
    • Jared W. Magnani,
    • Erin D. Michos,
    • Michael E. Mussolino,
    • Nisha I. Parikh,
    • Sarah M. Perman,
    • Mary Rezk-Hanna,
    • Gregory A. Roth,
    • Nilay S. Shah,
    • Mellanie V. Springer,
    • Marie-Pierre St-Onge,
    • Evan L. Thacker,
    • Sarah M. Urbut,
    • Harriette G.C. Van Spall,
    • Jenifer H. Voeks,
    • Seamus P. Whelton,
    • Nathan D. Wong,
    • Sally S. Wong,
    • Kristine Yaffe,
    • Latha P. Palaniappan,
    2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, Circulation, 151, 8, (2025).https://doi.org/10.1161/CIR.0000000000001303
    Crossref
    • Takeshi Yoshimoto,
    • Hiroshi Yamagami,
    • Yuji Matsumaru,
    Recent Advances in Stroke Genetics—Unraveling the Complexity of Cerebral Infarction: A Brief Review, Genes, 16, 1, (59), (2025).https://doi.org/10.3390/genes16010059
    Crossref
    • Di Wang,
    • Nicolas Honnorat,
    • Jon B Toledo,
    • Karl Li,
    • Sokratis Charisis,
    • Tanweer Rashid,
    • Anoop Benet Nirmala,
    • Sachintha Ransara Brandigampala,
    • Mariam Mojtabai,
    • Sudha Seshadri,
    • Mohamad Habes,
    Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer’s, vascular and Lewy body dementias, Brain, (2024).https://doi.org/10.1093/brain/awae388
    Crossref
    • Nazia Pathan,
    • Muskaan Kaur Kharod,
    • Sajjha Nawab,
    • Matteo Di Scipio,
    • Guillaume Paré,
    • Michael Chong,
    Genetic Determinants of Vascular Dementia, Canadian Journal of Cardiology, 40, 8, (1412-1423), (2024).https://doi.org/10.1016/j.cjca.2024.03.025
    Crossref
    • Maryam Rahmani,
    • Donna Dierker,
    • Lauren Yaeger,
    • Andrew Saykin,
    • Patrick H. Luckett,
    • Andrei G. Vlassenko,
    • Christopher Owens,
    • Hussain Jafri,
    • Kyle Womack,
    • Jurgen Fripp,
    • Ying Xia,
    • Duygu Tosun,
    • Tammie L. S. Benzinger,
    • Colin L. Masters,
    • Jin-Moo Lee,
    • John C. Morris,
    • Manu S. Goyal,
    • Jeremy F. Strain,
    • Walter Kukull,
    • Michael Weiner,
    • Samantha Burnham,
    • Tim James CoxDoecke,
    • Victor Fedyashov,
    • Jurgen Fripp,
    • Rosita Shishegar,
    • Chengjie Xiong,
    • Daniel Marcus,
    • Parnesh Raniga,
    • Shenpeng Li,
    • Andrew Aschenbrenner,
    • Jason Hassenstab,
    • Yen Ying Lim,
    • Paul Maruff,
    • Hamid Sohrabi,
    • Jo Robertson,
    • Shaun Markovic,
    • Pierrick Bourgeat,
    • Vincent Doré,
    • Clifford Jack Mayo,
    • Parinaz Mussoumzadeh,
    • Chris Rowe,
    • Victor Villemagne,
    • Randy Bateman,
    • Chris Fowler,
    • Qiao-Xin Li,
    • Ralph Martins,
    • Suzanne Schindler,
    • Les Shaw,
    • Carlos Cruchaga,
    • Oscar Harari,
    • Simon Laws,
    • Tenielle Porter,
    • Eleanor O’Brien,
    • Richard Perrin,
    • Walter Kukull,
    • Randy Bateman,
    • Eric McDade,
    • Clifford Jack,
    • John Morris,
    • Nawaf Yassi,
    • Pierrick Bourgeat,
    • Richard Perrin,
    • Blaine Roberts,
    • Victor Villemagne,
    • Victor Fedyashov,
    • Benjamin Goudey,
    Evolution of white matter hyperintensity segmentation methods and implementation over the past two decades; an incomplete shift towards deep learning, Brain Imaging and Behavior, 18, 5, (1310-1322), (2024).https://doi.org/10.1007/s11682-024-00902-w
    Crossref
    • Quentin Le Grand,
    • Ami Tsuchida,
    • Alexandra Koch,
    • Mohammed-Aslam Imtiaz,
    • N. Ahmad Aziz,
    • Chloé Vigneron,
    • Laure Zago,
    • Mark Lathrop,
    • Alexandre Dubrac,
    • Thierry Couffinhal,
    • Fabrice Crivello,
    • Paul M. Matthews,
    • Aniket Mishra,
    • Monique M. B. Breteler,
    • Christophe Tzourio,
    • Stéphanie Debette,
    Diffusion imaging genomics provides novel insight into early mechanisms of cerebral small vessel disease, Molecular Psychiatry, 29, 11, (3567-3579), (2024).https://doi.org/10.1038/s41380-024-02604-7
    Crossref
    • Seth S. Martin,
    • Aaron W. Aday,
    • Zaid I. Almarzooq,
    • Cheryl A.M. Anderson,
    • Pankaj Arora,
    • Christy L. Avery,
    • Carissa M. Baker-Smith,
    • Bethany Barone Gibbs,
    • Andrea Z. Beaton,
    • Amelia K. Boehme,
    • Yvonne Commodore-Mensah,
    • Maria E. Currie,
    • Mitchell S.V. Elkind,
    • Kelly R. Evenson,
    • Giuliano Generoso,
    • Debra G. Heard,
    • Swapnil Hiremath,
    • Michelle C. Johansen,
    • Rizwan Kalani,
    • Dhruv S. Kazi,
    • Darae Ko,
    • Junxiu Liu,
    • Jared W. Magnani,
    • Erin D. Michos,
    • Michael E. Mussolino,
    • Sankar D. Navaneethan,
    • Nisha I. Parikh,
    • Sarah M. Perman,
    • Remy Poudel,
    • Mary Rezk-Hanna,
    • Gregory A. Roth,
    • Nilay S. Shah,
    • Marie-Pierre St-Onge,
    • Evan L. Thacker,
    • Connie W. Tsao,
    • Sarah M. Urbut,
    • Harriette G.C. Van Spall,
    • Jenifer H. Voeks,
    • Nae-Yuh Wang,
    • Nathan D. Wong,
    • Sally S. Wong,
    • Kristine Yaffe,
    • Latha P. Palaniappan,
    2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, Circulation, 149, 8, (e347-e913), (2024).https://doi.org/10.1161/CIR.0000000000001209
    Crossref
    • Chih-Ping Chung,
    • Masafumi Ihara,
    • Saima Hilal,
    • Liang-Kung Chen,
    Targeting cerebral small vessel disease to promote healthy aging: Preserving physical and cognitive functions in the elderly, Archives of Gerontology and Geriatrics, 110, (104982), (2023).https://doi.org/10.1016/j.archger.2023.104982
    Crossref
    • Connie W. Tsao,
    • Aaron W. Aday,
    • Zaid I. Almarzooq,
    • Cheryl A.M. Anderson,
    • Pankaj Arora,
    • Christy L. Avery,
    • Carissa M. Baker-Smith,
    • Andrea Z. Beaton,
    • Amelia K. Boehme,
    • Alfred E. Buxton,
    • Yvonne Commodore-Mensah,
    • Mitchell S.V. Elkind,
    • Kelly R. Evenson,
    • Chete Eze-Nliam,
    • Setri Fugar,
    • Giuliano Generoso,
    • Debra G. Heard,
    • Swapnil Hiremath,
    • Jennifer E. Ho,
    • Rizwan Kalani,
    • Dhruv S. Kazi,
    • Darae Ko,
    • Deborah A. Levine,
    • Junxiu Liu,
    • Jun Ma,
    • Jared W. Magnani,
    • Erin D. Michos,
    • Michael E. Mussolino,
    • Sankar D. Navaneethan,
    • Nisha I. Parikh,
    • Remy Poudel,
    • Mary Rezk-Hanna,
    • Gregory A. Roth,
    • Nilay S. Shah,
    • Marie-Pierre St-Onge,
    • Evan L. Thacker,
    • Salim S. Virani,
    • Jenifer H. Voeks,
    • Nae-Yuh Wang,
    • Nathan D. Wong,
    • Sally S. Wong,
    • Kristine Yaffe,
    • Seth S. Martin,
    Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association, Circulation, 147, 8, (2023).https://doi.org/10.1161/CIR.0000000000001123
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text

View Full Text
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF